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ABSTRACT 
 
 
Acute lung inflammation (ALI), stemming from a disproportionate and 
detrimental immune response, may arise from or complicate other disease states, leading 
to the often-fatal acute respiratory distress syndrome (ARDS). Because of the many 
culpable factors and differing points of induction, pinning down the signaling 
mechanisms involved in the morbidity of this disorder as well as defining an effective 
treatment has proved problematic. However, the most detrimental characteristic of this 
condition is seen regardless of the development of the response: increased microvascular 
permeability. Because of the architecture and the size of the pulmonary microvascular 
network, the lungs have a resident, sequestered population of leukocytes that are able to 
rapidly respond to injury or infection, but may also contribute to the pathology of 
ALI/ARDS by increasing endothelial barrier dysfunction. Many inflammatory mediators 
dictate the course and gravity of the response by inducing endothelial cytoskeletal 
reorganization, such as induction of actin stress fibers, cell rounding and contraction, and 
dissociation of interendothelial junctions.  
 
Thrombin is a well-studied mediator that has been shown to be barrier-disruptive 
rapidly increases microvascular permeability. Sphingosin-1-phosphate (S1P) is a more 
novel, less understood mediator that has been shown to mediate basal vascular 
permeability as well as to enhance barrier integrity in inflammation. Inflammatory 
signaling may also expand throughout the lungs through intercellular communication via 
gap junctions composed of connexins, such as Connexin 43 (Cx43). Herein, we explored 
how intercellular communication through Cx43-containing gap junctions mediates 
thrombin-induced signaling as well as the interplay between thrombin- and S1P- induced 
signaling on the pulmonary microvascular barrier.  
 
We isolated and perfused lungs from rats and mice, a physiologically-relevant 
model to study lung inflammation. We found that focal micropuncture instillations of 
thrombin were able to induce responses related to hyperpermeability (including, changes 
in intracellular Ca2+, increased F-actin polymerization, and increased reactive oxygen 
species generation) both in microvessels directly treated with thrombin and those far 
outside the instilled region (up to 1000 μm away), and the expansion of signaling into the 
untreated microvessels was due to intercellular communication mediated by Cx43. For 
the F-actin polymerization response, we determined that the specific second messenger 
being communicated and propagating the thrombin-induced increase was inositol 
trisphosphate (IP3). We also found that, though thrombin induced increases in mean 
Ca2+in cultured cells, it instead induced increases in the amplitude of cytosolic Ca2+ 
oscillations in pulmonary microvessels. While we observed that untreated primary 
pulmonary microvascular endothelial cells and pulmonary microvessels from mice 
lacking endothelial Cx43 displayed higher levels of the S1P receptor, S1P2, thrombin 
induced an increase in S1P2 expression that was dependent on the presence of Cx43. 
While S1P itself was able to partially rescue barrier integrity following thrombin 
treatment, we show for the first time that S1P2 signaling substantially contributes to 
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thrombin-induced endothelial hyperpermeability, and that inhibiting S1P2 significantly 
reduced thrombin-induced permeability increases.  
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CHAPTER 1.    INTRODUCTION 
 
 
Lung Inflammation 
 
Although unchecked inflammation leading to endothelial barrier disruption can be 
detrimental throughout the body, inflammation in the lungs can be particularly hazardous 
and life threatening. Acute lung inflammation (ALI), and its more grave form acute 
respiratory distress syndrome (ARDS), results from extensive inflammation in the lungs 
that is associated with increased microvascular permeability, alveolar flooding, and 
impaired gas exchange[1, 2]. While these conditions have been extensively studied, 
ARDS maintains a high morbidity and mortality rate, particularly in critically ill patients 
where this severe lung inflammation occurs secondary to other conditions, such as sepsis, 
shock, or high-risk surgery [3, 4]. Despite advancements in understanding of the 
pathophysiology ALI/ARDS, advancements in treatment have been sparse. The incidence 
in intensive care unit patients and mortality of ARDS has not significantly lessened since 
it was first described in 1967[3, 5, 6]. Treatment is largely supportive, dependent on 
symptom management and mechanical ventilation, and, due to the heterogeneity in the 
development and presentation of severe pulmonary inflammation, pharmacological 
interventions are lacking [6-8]. Understanding the development and progression of this 
injurious condition, specifically within the pulmonary microvasculature, has been and 
remains crucial to combating this hyperinflammatory event. 
 
 
Pulmonary Vasculature 
 
The endothelial barrier is composed of a monolayer of endothelial cells in close 
association with one another through interendothelial junctions, specifically adherens 
junctions (AJs) and tight junctions (TJs), formed through the homotypic association of 
the protein components in the plasma membrane of adjacent endothelial cells[9]. The 
semi-permeability of the endothelial barrier is due to the presence of these 
interendothelial junctions which allow the endothelium to regulate the paracellular 
passage of small molecules[10]. AJs, which account for approximately 80% of 
interendothelial junction complexes, are formed from the interaction of vascular 
endothelial cadherin (VE-cadherin) proteins between neighboring endothelial cells; TJs 
are similarly composed of members of either the occludin or claudin protein families [4, 
9]. AJs, as well as TJs, are able to associate with the cytoskeleton via members of the 
actin-binding protein families catenins and zonula occludens, respectively[10]. In the 
normal pulmonary endothelium, cytoskeletal tethering forces within and between 
endothelial cells help to maintain the tight vascular barrier, and the association between 
VE-cadherin and the cortical actin band helps to strengthen the AJs[1, 9]. However, in 
inflammation, cytoskeletal rearrangement and formation of actin stress fibers leads to 
endothelial cell contraction and the disruption of AJs, which promotes formation of 
interendothelial gaps and an increase in permeability[9].  
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Compared to other organ systems, the lungs possess the highest ratio of 
endothelial cells to other resident cell types[11]. This is due to the large, dense capillary 
network required for the gas exchange that takes place here. In the alveolar capillaries, 
the endothelial cells are particularly thin and are typically separated from the airway cells 
only by the basement membrane[12]. In addition, the pulmonary capillaries are generally 
narrower than what is seen in the systemic vasculature and are subject to lower perfusion 
pressures [11, 13, 14]. Because of this specific organization in the lung, under normal 
conditions there remains a large pool of leukocytes, including neutrophils, monocytes, 
and lymphocytes, within the microvasculature, and this allows for a more rapid immune 
response during inflammation[15]. However, also because of the organization of the lung 
capillaries, these marginated immune cells may wreak havoc on the endothelium during 
inflammation, releasing pro-inflammatory mediators and toxic oxidant species that 
contribute to endothelial apoptosis and increased permeability [1, 16]. As a short 
diffusion distance is essential for adequate oxygenation of blood flowing in pulmonary 
capillaries, increased permeability and edema in these tissues carries severe body-wide 
consequences. 
 
 
Initiation of Lung Inflammation 
 
Given that the airways are directly and continuously exposed to the environment, 
as well as the size and proximity of the vasculature, this substantial population of 
endothelial cells are particularly vulnerable to infection and injury [1]. Lung 
inflammation, including the cases that proceed to ALI and ARDS, may be initiated 
through two routes, either direct or indirect injury to the lung [1, 6, 17]. Because of the 
assortment of different conditions and insults that can have lung inflammation as an end 
result, it is difficult to outline the particular events leading up to the more fatal cases [17]. 
However, the defining and most critical characteristic is the increased pulmonary 
microvascular permeability, and the other major side effects of alveolar flooding, 
decreased gas exchange, and lung edema, are either a result of or worsened by this 
principal dysfunction [10, 18, 19]. See Table 1-1 for a list of various causes of severe, 
detrimental lung inflammation. 
 
Two major events that may lead to severe lung inflammation are sepsis and injury 
caused by mechanical ventilation. Sepsis is the systemic inflammatory response to 
infection, and is the most prevalent cause of ICU deaths that has ALI/ARDS as a 
comorbidity [8, 20-24]. In infection, pathogen-associated molecular patterns (PAMPs), 
typically consisting of bacterial or fungal cell wall components, are recognized by 
pattern-recognition receptors (PRRs) expressed on various cell types, including 
endothelial. [25-27]. The best studied examples of these are the PAMP 
lipopolysaccharide (LPS) which is recognized by the PRR toll-like receptor 4 (TLR4). 
Lung inflammation and sepsis go hand-in-hand: while Gram-negative sepsis is the most 
common cause of ARDS, bacterial pneumonia may also cause sepsis [19, 28, 29]. Cecal 
ligation and puncture (CLP) models of sepsis have shown that there is an upregulation of 
the RhoA effector protein Rho kinase 1 (ROCK1), which can contribute to increased  
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Table 1-1. Direct and indirect causes of severe lung inflammation 
 
Direct Indirect 
Infectious pathogens (ex. 
lipopolysaccharide)[7, 30] 
Ischemia/reperfusion[2] 
Aspiration injury[8, 17, 22, 30] Pancreatitis[8] 
Allergens[30] Severe burns[8] 
Toxic gases[8, 30] Mass transfusion[8, 22] 
Barotrauma/Volutrauma[30] Sepsis[2, 4, 7, 17, 22, 31] 
Mechanical ventilation injury[8, 22, 30] Severe trauma/Shock[8, 17, 22] 
Pneumonia[7, 8, 17, 22] Drug reactions/overdose[8, 22] 
Lung contusions[8, 22, 30] Multiple/long bone fractures[8] 
Airway obstruction[8] Cardiopulmonary bypass[8] 
Fat emboli[22]  
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microvascular permeability by disrupting AJs and endothelial cell contraction [10, 32, 
33]. There is also increased activation of the coagulation cascade in sepsis, which may 
contribute to microthrombus formation and microvascular occlusion [2, 10]. 
 
While mechanical ventilation is a major intervention in treating many critical 
illnesses, it may worsen or even cause severe lung inflammation and injury in what is 
termed ventilator-induced lung injury (VILI) [8, 29]. In the past, mechanical ventilation 
was given with high tidal volumes, which has been shown to induce pro-inflammatory 
responses, leading to an increase in adhesion molecules on lung microvascular 
endothelial cells, as well as over-inflation of the alveoli [22, 30]. In one study in mice 
infected with Streptococcus pneumoniae, mechanical ventilation resulted in increased 
lung permeability and decreased blood oxygenation compared to mice with pneumonia 
alone [29]. In cases where inflammation in the lung has already progressed to the point 
that there is increased vascular permeability or edema, blood flow in the area may be 
compromised to the point which mechanical ventilation yields ventilation-perfusion 
mismatch [1]. This ventilator dead space contributes to the over-inflation of the lungs 
such that the endothelial cells become stretched, damaging both already inflamed tissues 
as well as unaffected areas [1, 8]. However, low tidal volumes also carry risks because of 
the necessary increase in respiratory rates that may lead to hypercapnia [22, 29]. Current 
strategies to prevent VILI involve low tidal volume with high positive end-expiratory 
pressure (PEEP), which combined help to mitigate overstretch injury as well as the 
collapse of alveoli [8, 34-36].  
 
 
Mechanisms of Endothelial Barrier Dysfunction 
 
A major path through which increased permeability is achieved is through 
endothelial cytoskeletal remodeling. Inflammatory mediators induce endothelial 
activation, which often includes the involvement of Rho family GTPases, RhoA and 
Rac1 [9, 37]. In healthy endothelium, Rac1 is the predominant active GTPase regulating 
the actin cytoskeleton in a barrier-protective manner, mediating the stability of  the 
cortical actin band as well as the association between the actin cytoskeleton and the 
AJs/TJs[9]. In disease states, inflammatory mediators induce the activation of the RhoA, 
and its downstream effector ROCK, which affects actin dynamics in a barrier-
destabilizing manner [9, 10]. In addition to promoting actin stress fiber formation over 
cortical actin band formation, RhoA induces endothelial cell contraction and rounding 
[10, 37]. Hepatocyte growth factor (HGF) induces the activation of Rac1, and in a two-hit 
model of ALI (induction of VILI and treatment with thrombin), treatment with HGF 
decreased lung vascular leak and infiltration of immune cells into lung tissue [38]. ExoS 
and ExoT, the cytotoxins responsible for increases in permeability associated with 
Pseudomonas aeruginosa-induced lethal pneumonia, were found to significantly decrease 
Rac1 activation and increase RhoA activation within 10 minutes of treatment in lung 
endothelial monolayers [39]. 
 
Inflammatory mediators, particularly those activating G-protein coupled 
receptors, will also induce an increase in intracellular Ca2+ through the emptying of 
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internal Ca2+ stores [40]. This emptying of Ca2+ stores is able to, in turn, stimulate 
external calcium entry through the activation of transient receptor potential canonical 
(TRPC) channels [9] A major TRPC protein in the endothelium is TRPC6. LPS 
activation of TLR4 subsequently leads to an increase in Ca2+, and LPS airway instillation 
was unable to induce increases in lung permeability in a TRPC6 knockout mouse line 
[41].The increase in Ca2+ leads to the Ca2+/calmodulin dependent activation of myosin 
light chain kinase (MLCK), which phosphorylates myosin II [37]. Through this the 
actomyosin motor is activated which increases intracellular tension through the cross-
bridging interactions between actin and myosin fibers. This subsequently results in the 
pulling apart of the interendothelial junctions and contributes to the rounding of 
endothelial cells [9, 37]. 
 
In addition to the changes to the cytoskeleton due to endothelial cell activation by 
pro-inflammatory mediators, damage caused by leukocytes is also a major contributor to 
increases in microvascular permeability. As explained earlier, the unique architecture of 
the lung capillary network creates an environment where leukocytes (specifically 
neutrophils) may become marginated and is also the site of leukocyte migration into 
targeted tissues. In normal endothelium, there is some baseline expression of adhesion 
molecules but intravascular shear forces and the endothelial glycocalyx prevent leukocyte 
adhesion as well as adhesion molecules exposure; in inflammation, however, activated 
endothelial cells upregulate production of chemokines and adhesion molecules (such as 
P-selectin, E-selectin, and ICAM1) presented on the luminal surface and various pro-
inflammatory mediators also initiate loss of proteins composing the glycocalyx, further 
exposing the adhesion molecules[1, 13, 42-45]. Increases in these responses result in 
recruitment and accumulation of leukocytes at the targeted tissues [24, 44].  
 
Traditionally, the steps in leukocyte movement across the endothelial barrier are 
rolling, adhesion, and diapedesis. Neutrophils, however, are typically wider than the 
pulmonary capillary diameter, and they must undergo a shape change to pass through 
[11-13]. Activation of the neutrophils during inflammation only increases their stiffness 
and therefore the transit time through the microvasculature [13, 40]. For this reason, 
while other systemic beds see neutrophil extravasation primarily in post-capillary 
venules, in the lungs this is primarily observed in the capillaries, and rolling is not 
thought to occur in this transendothelial migration [11, 26, 40, 42]. Neutrophils trapped in 
these capillaries can result in microvascular blockage and contribute to hyperpermeability 
through the release of cytotoxic agents, such as reactive oxygen species (ROS), 
antimicrobial peptides, proteases, and lytic enzymes [46, 47]. In addition, neutrophils 
have been shown to undergo a specific type of cell death in which they extrude neutrophil 
extracellular traps (NETs): nuclear DNA strands in web-like structures that act to entrap 
pathogens [47, 48]. NETs have been shown to further induce cytotoxicity and endothelial 
cell death, in addition to contributions to permeability and microvascular occlusion [47]. 
In one study of transfusion-related ALI, antibodies directed against histones (a 
component of NETs) lead to reduced lung edema and mortality[48]. In sepsis, depletion 
of neutrophils has been shown to be protective to the lungs [1, 13, 26]. In one influenza 
model of ALI, neutrophil-depleted mice showed no signs of respiratory distress or 
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development of NETs [49]. Thus, while immune cells are necessary for recovery, 
overzealous activation of leukocytes may exacerbate inflammation.  
 
 
Common Inflammatory Mediators Affecting Microvascular Permeability 
 
While there are many causes and factors that may precede lung inflammation, the 
signaling involved is often initiated by the same common inflammatory mediators. 
 
In inflammation, the coagulation cascade is activated and leads to the production 
of thrombin at sites of pulmonary microembolism [1, 50]. Within the coagulation 
cascade, the serine protease thrombin cleaves fibrinogen to fibrin, allowing for fibrin 
deposition and clotting [2, 51, 52]. Thrombin binds protease-activated receptor-1 (PAR-
1), a G-protein coupled receptor [50]. Activation of PAR-1 leads to generation of inositol 
trisphosphate (IP3), which then binds its receptors at the endoplasmic reticulum (ER) and 
causes ER store Ca2+ release as well as subsequent external Ca2+ entry.. This increase in 
intracellular calcium has been shown to underlie the thrombin-induced actions of 
endothelial cell contraction, increased microvascular permeability, and increased actin 
polymerization and stress fiber formation [53, 54]. In addition, activation of PAR-1 by 
thrombin also induces activation of NADPH oxidase 2 (Nox2), leading to the production 
of ROS, and activation of RhoA, both of which further contribute to thrombin-induced 
disruption of AJs and increases in barrier permeability [10, 51].  
 
LPS, as mentioned earlier, is an essential component of Gram-negative bacterial 
cell walls (ex: Escherichia coli) that is recognized by and activates TLR4 on endothelial 
cells [41, 55]. TLR4 activation has been shown to induce the decreased expression of 
VE-cadherin and the disruption of AJs, and initiates the activation of pro-inflammatory 
signaling pathways leading to cytokine expression and microvascular barrier disruption 
through RhoA/ROCK activation [19, 41, 56] In a study using human microvascular 
endothelial cells in culture, inhibiting ROCK prevented the LPS-induced MLC 
phosphorylation and decrease in transendothelial resistance [10]. In an in vivo study in 
which LPS was injected intravenously to induce ALI, blocking ROCK attenuated both 
LPS-induced lung edema and neutrophil emigration [33]. Another pro-inflammatory 
mediator that induces endothelial barrier disruption is tumor necrosis factor alpha 
(TNFα). TNFα is an early inflammatory cytokine that activates its receptor TNFR1 on 
endothelial cells [19, 45, 57]. TNFα induces expression of other inflammatory mediators 
(such as ICAM1, IL-1β, and IL-8) through activation of the transcription factor NF-κB, 
as well as induces the degradation of the endothelial glycocalyx through the activation of 
heparanase [45, 57]. In endothelial cells, TNFα can also induce the formation of actin 
stress fibers [26]. While the concentration of TNFα in BAL fluid has been shown to 
correlate with the development of ALI/ARDS, a clinical trial of a monoclonal antibody 
directed against it did not show improved survival rates [58, 59]. 
 
One example of a barrier-protective inflammatory mediator is cyclic adenosine 
monophosphate (cAMP) [9]. cAMP is a second messenger generated from ATP by 
adenylate cyclase (AC) at the plasma membrane and is degraded by phosphodiesterases. 
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cAMP has been shown to stabilize the cortical actin ring and strengthen interendothelial 
junctions, and decrease or prevent the expression of pro-inflammatory cytokines, leading 
to increased endothelial barrier integrity in inflammation[28]. Pretreatment with the AC 
activator forskolin significantly decreased the ability of LPS to induce hyperpermeability 
in human lung microvascular endothelial cells in culture [55]. In a CLP-sepsis induction 
of ALI, increases in permeability could be blocked by using a phosphodiesterase inhibitor 
[60]. While generation of cAMP at the membrane induces barrier-protective effects, lung 
microvascular endothelial cells also express a soluble form of AC (AC10) that exists in 
the cytosol [28]. Activation of AC10 has been shown to induce increased microvascular 
permeability and may be stimulated by the presence of bicarbonate. In one ex vivo model 
of LPS-induced lung inflammation, increases in permeability could be prevented with the 
use of an AC10 inhibitor or removal of bicarbonate from the perfusate [28].   
 
Sphingosine-1-phosphate (S1P) is a lysophospholipid signaling molecule that is 
involved in the regulation of a multitude of cellular processes including embryonic 
vascular development, cell proliferation and motility, angiogenesis, and immune and 
allergic responses [61-65]. The expression of S1P, as well as its receptors and enzymes 
involved in its synthesis, has been found to be increased in inflammation and cancer [65, 
66]. S1P is derived from the deacetylation of ceramide to sphingosine, followed by 
phosphorylation by sphingosine kinase (SphK) [67].Two isoforms of SphK exist, SphK1 
and SphK2, with SphK1 being the most abundant as well as the rate-limiting enzyme in 
S1P synthesis [62, 67]. The receptors for S1P are a family of G-protein coupled receptors 
(S1P1-5) that are expressed in a variety of cell types, particularly in endothelial cells [62]. 
S1P1 is the predominate receptor in endothelial cells, and is by far the most extensively 
studied [68]. One of the main contributions of S1P1 in endothelial cells is enhancement 
of the endothelial barrier. S1P1 signals exclusively through Gαi, resulting in activation of 
Rac1 [61, 69]. This leads to enhancement of the endothelial barrier through translocation 
of VE-cadherin to AJs, cytoskeletal rearrangement, and subsequent spreading of 
endothelial cells to close interendothelial gaps [37, 61]. In contrast, S1P2, another S1P 
highly expressed receptor in endothelial cells, signals through Gαi as well as Gαq and 
Gα12/13, which leads to preferential activation of RhoA over Rac1 [61, 69]. This evokes 
opposite, barrier destructive effects of disruption of AJs, endothelial cell contraction, and 
induction of actin stress fibers [9, 37, 61]. Because of the opposing responses following 
activation of the two S1P receptors, the balance of S1P1 and S1P2 signaling is said to 
maintain vascular tone [66, 70, 71]. However, because of the larger role of the S1P1 
receptor, S1P is generally considered a barrier-supportive inflammatory mediator [62]. 
 
 
Expansion of Inflammatory Signaling 
 
Excessive inflammation can spread outside of the injured or infected tissues to 
surrounding healthy tissues [72]. This expansion of inflammatory signaling can be 
observed in ARDS. One of the requirements for a diagnosis is the presence of bilateral 
infiltrates in the lungs, observed in chest radiographs as opacities in both lungs [3, 7, 73]. 
This suggests that not only is inflammation spreading throughout a lung, but also that this 
signaling is able to spread between the two lungs. While the reason for this spread of 
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inflammation is unclear, recent evidence points to the movement of second messengers 
through gap junctions as the causative mechanism. 
 
Gap junctions facilitate the direct exchange of ions and small molecules between 
adjacent cells [74]. They are composed of connexin subunits; 6 connexins form 1 
hemichannel or connexon, and connexons from two adjacent cells form the functioning 
gap junction channel [75]. Gap junctions are known to allow the propagation of signaling 
molecules in a variety of cell types [76-78]. In pulmonary endothelium, Connexin 43 
(Cx43) is abundantly expressed and has been shown to be the major connexin involved in 
the spread of inflammatory signaling. Increases in endothelial permeability induced by 
the inflammatory mediators, thrombin and LPS occurred in tandem with increases in 
Cx43 expression, and inhibiting intercellular communication through gap junctions 
mitigates the increases in permeability [56, 79-81]. Cx43-containing gap junctions clearly 
contribute to the spatial expansion of inflammatory signaling, and as more is elucidated 
as to the exact mechanisms involved in this propagation of signaling, such as specific 
second messengers involved, new and more-effective therapies may be developed to limit 
it. 
 
 
Specific Aims 
 
For as much as has been studied on this ubiquitous inflammatory event, the many 
gaps of that knowledge allow severe lung inflammation to remain an often deadly 
condition. Increased microvascular permeability has been shown to be the most common 
symptom, regardless of etiology. However, many of the traditional methods of studying 
the specific responses within the endothelium are unable to adequately capture or 
illustrate the mechanism behind endothelial monolayer disruption. To that end, the goal 
of this project is to study signaling induced by inflammatory mediators in a 
physiologically relevant model to elucidate signaling molecules involved in the 
hyperpermeability response. This will be specifically addressed by employing the 
isolated perfused rodent lung model to: 
 
1. Define spatially-expansive, barrier-disruptive signaling induced by thrombin 
2. Determine specific second messengers mediating this spatial expansion 
3. Explore the interplay between signaling induced by both thrombin and S1P 
 
These points will all be addressed in the following with the intention of identifying 
previously unknown mechanisms by which excessive inflammatory responses may be 
curtailed. 
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CHAPTER 2.    THE ISOLATED PERFUSED RODENT LUNG MODEL 
 
 
 The majority of what we know about inflammatory signaling processes comes 
from studies done in cell cultures. Barrier permeability in particular lends itself easily to 
experiments using endothelial monolayers grown on transwell inserts, allowing for 
precise measurement of the passage of molecules from the apical to basal compartments. 
There are numerous advantages to studying inflammatory signaling in cells: there are 
established cell lines readily available; cell culture itself is relatively easy and 
inexpensive; and a large scale of results may be obtained in a short amount of time. 
However, both the conditions in which cells are cultured and the results obtained therein 
may not always coincide with in vivo observations. Cultured endothelial cells may lose 
their phenotype with successive passages and are missing the interactions with other cell 
types within their respective tissues [18]. In addition, some studies rely on endothelial 
cells that originate from completely different organs, such as using HUVECs to make 
determinations about lung inflammation [82-85]. In short, there is a vacuum for more 
physiologically-relevant methods. 
 
One such solution for this would be studies employing intravital microscopy of 
the lung, in which a sedated and anesthetized animal has a transparent window implanted 
in their thoracic cavity allowing for imaging [31]. However, imaging with this specific 
technique is complicated by the constant movement of the lungs, due to blood flow and 
ventilation. However, these obstacles are removed in the isolated perfused lung (IPL) 
model. IPL is an ex vivo model in which the lungs are surgically removed from the 
animal, perfused at a constant rate, and kept constantly inflated [31, 86]. Maintaining 
continuous physiological pressures in the airways and vasculature allows for a highly 
stable surface that is well-suited for imaging, and the results gained from this model more 
closely mimic in vivo observations compared to monolayer studies [84, 86]. 
 
 
Surgery and Set Up 
 
Prior to surgery, the perfusion system is set up at the microscope, and the 
perfusate media (used to supplement the collected, autologous blood) is warmed to 37°C. 
After sedating and anesthetizing the rat or mouse, the trachea of the rodent is cannulated. 
Next, the skin covering the chest is removed. Heparin is injected directly into the heart 
(.5-1mg), allowed to circulate for approximately 30 seconds, and then the now-
heparinized blood is collected through the same syringe. Following this, either the ventral 
chest wall is severed longitudinally and kept open with a rib separator (in the rat), or the 
ribs are cut away entirely (in the mouse). Incisions are made in the heart first below the 
opening of the pulmonary artery and then at the apex of the heart. Through these 
incisions cannulae are placed in the pulmonary artery and into the left atrium, 
respectively. Finally, the trachea is severed above the cannula, and the lungs and heart are 
excised. They are then placed in a dish containing gauze that has been pre-wet with 
saline. This dish is then transferred to the microscope and perfusion system. 
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Immediately following transfer, the pulmonary artery and left atrial cannulae are 
connected to the perfusion tubing and the tracheal cannula is connected to a separate 
airway tubing. Prior to the start of perfusion, the lungs are inflated with room air. The 
collected blood is added into the pre-warmed perfusate media, and the peristaltic pump 
(which evenly and continuously directs flow through the pulmonary artery cannula and 
out the left atrial cannula) is started (Figure 2-1). The perfusate media used to replace or 
supplement the autologous blood, in addition to being pre-warmed, also contains sugars, 
physiological salts, and albumin to maintain cellular processes, pH, and permeability [86, 
87]. 
 
 
Delivery of Dyes and Reagents to Pulmonary Microvessels 
 
The physical stability of the IPL is ideal for microscopy studies, and this method 
is often employed in real-time fluorescence imaging experiments. While fluorescent dyes 
may be added directly to the perfusate, it is often more prudent to expose and image only 
a section of the microvasculature. There are three main methods to accomplish this: 
superfusion, catheter infusion, and micropuncture instillations. 
 
In superfusion, a catheter connected to a syringe pump is suspended above the 
lung. The reagent is then allowed to drip directly onto the lung surface (Figure 2-2). 
Normally, the lung surface will be first fixed and/or permeabilized to ensure effective 
distribution of dyes or antibodies to the microvessels. Catheter infusions allow for a more 
controlled delivery of reagents. With this method, a microcatheter is fed through the left 
atrium and wedged into the microvasculature. Because red blood cells in the 
microvasculature may block or obscure fluorescence, microvessels are first cleared of 
these cells by an infusion of perfusate media prior to delivery of fluorescence dyes or 
reagents. (Figure 2-3).  The most delicate and precise method is micropuncture 
instillations. The beveled tip of a glass micropipette connected via tubing to a syringe is 
used to pierce a post-capillary venule (approximately 20μm in width) (Figure 2-4). The 
instilled reagent is mixed with a fluorescent dye, and the size of the instillation is viewed 
through the microscope and regulated by the pressure used to compress the syringe. This 
also allows for precise delineation of the microvessels receiving the substance. These 
methods are sometimes used in conjunction with one another, such as first clearing a 
section of the vasculature via a catheter before performing micropuncture. 
 
In summary, IPL is an ex vivo method in which the microenvironment is 
maintained to replicate different physiological parameters to what is observed in vivo. 
Several techniques are employed to supply controlled and precise delivery of dyes and 
reagents to pulmonary microvessels, allowing for fluorescence studies that provide 
results more closely related to what is seen in the organism compared to what is observed 
in cell culture studies. 
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Figure 2-1. Diagram of perfusion set up in IPL 
Diagram showing the isolated lungs and the flow of blood and media through the 
perfusion system. Beginning at the perfusate reservoir, the blood and perfusate media 
passes through the peristaltic pump. The pump thrusts the liquid forward at a constant 
rate and pressure, as opposed to the pulsation pumping of the heart. The liquid then 
passes through an air trap which eliminates air bubbles, thereby preventing pulmonary 
embolism. The tubing section following the pump is gathered in a spiral such that the 
perfusate media flowing through spends a prolonged time in the 37°C water bath. The 
perfusate then is pumped into the lungs through the pulmonary artery cannula, circulates, 
and then is pumped back out through the left atrial cannula. The pressure in the tubing 
connected to the pulmonary artery and the left atrial cannulae, as well as the tubing 
connected to the tracheal cannula, is monitored via a pressure transducer. The pressures 
in the pulmonary artery, left atrial, and tracheal tubing are maintained at 3 cm H2O, 10 
cm H2O, and 5 cm H2O respectively. 
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Figure 2-2. Delivery of dyes via superfusion 
Image depicts set up for superfusion delivery of dyes and reagents to the mouse lung 
surface. A PE10 microcatheter (white arrow) is affixed to a coverslip holder (black 
arrow), and the superfusate is allowed to drip directly onto the lung tissue. Under the 
microscope, the edge of the catheter may be precisely positioned to a targeted 
microvascular bed at the lung surface.  
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Figure 2-3. Delivery of dyes via microcatheter 
Diagrams and image showing placement of microcatheter into pulmonary microvessels. 
(A) Diagram depicts the placement of the PE10 microcatheter through the LA cannula. 
The microcatheter is attached to a filled syringe on a pump. Inset shows cleared area 
following catheter delivery of HBS. (B) Diagram depicts microcatheter wedged into a 
larger vessel and delivering an infusion to all smaller, branching microvessels. 
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Figure 2-4. Delivery of dyes via micropuncture 
Images showing micropuncture delivery of fluorescent dye. (A) Image shows set up of 
micropuncture. Here, blue light is used to identify the tip of the micropipette (black 
arrows) under the microscope. (B) Confocal image following micropuncture instillation 
delivery of fluorescent dye into microvasculature. Filled micropipette is visible (white 
arrows). Bar – 50 μm. 
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CHAPTER 3.    THROMBIN INDUCES INOSITOL TRISPHOSPHATE-
MEDIATED SPATIALLY EXTENSIVE RESPONSES IN LUNG 
MICROVESSELS* 
 
 
Introduction 
 
Compartmentalization is being increasingly recognized as a mechanism for 
eliciting unique responses via a similar set of second messengers. In this regard, cellular 
signaling that results from activation of plasma membrane receptors may depend on 
compartmentalized regulation of second messengers. Thus, experimental models that 
induce second messenger increases throughout an entire cell may be inadequate 
substitutes to elucidate responses resulting from receptor-mediated increases in second 
messengers.   
 
Intercellular diffusion of second messengers, including Ca2+, IP3, cAMP, and 
ATP, facilitates the induction of responses at sites remote from the stimulus site and also 
coordinates responses among a larger group of cells [88-92]. The predominant second 
messenger is dependent on the stimulus and defines the remote response. For example, in 
lungs, remote induction of pulmonary arteriolar vasoconstriction by hypoxia is mediated 
by membrane depolarization [93, 94]. In contrast, induction of P-selectin expression and 
surfactant secretion in response to cell-wide increases in Ca2+ depends on intercellular 
diffusion of Ca2+ [81, 90, 95]. In the latter studies that implicate Ca2+ as the diffusing 
second messenger, the cell-wide Ca2+ increases were achieved by photolytic uncaging of 
Ca2+ in single cells. However, since Ca2+ signaling is compartmentalized, other second 
messengers may predominate in the induction of remote responses when intracellular 
Ca2+ increases are elicited via activation of plasma membrane receptors. To delineate this 
possibility, alternate models that activate specific plasma membrane receptors on cells 
located within a spatially restricted region may need to be utilized. 
 
In lung inflammation, a variety of inflammatory mediators activate G-protein 
coupled receptors and induce the release of ER-stored Ca2+. In the case of thrombin and 
PAR-1 activation, this increase in intracellular Ca2+ drives the increases in microvascular 
permeability as well as F-actin formation [96-98]. Given the compartmentalization 
intrinsic to Ca2+ signaling and that thrombin induces both IP3 generation and Ca2+ release, 
we utilized thrombin to define the specific second messenger diffusing through 
endothelial connexin-containing gap junctions. 
 
In the lungs, the gap junction protein Cx43 is abundantly expressed, and 
intercellular communication through Cx43-containing gap junctions has been shown to  
-------------------- 
*Reprinted from The American Journal of Pathology. Vol 187 /4. Rachel Escue, 
Kathirvel Kandasamy, and Kaushik Parthasarathi. Thrombin Induced Inositol 
Trisphosphate-Mediated Spatially Extensive Response in Lung Microvessels, 921-935, 
Copyright (2017), with permission from Elsevier  
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mediate the expansion of inflammatory signaling [79, 80]. In studies focusing on lung 
microvessels, Cx43 has been shown to mediate the Ca2+-dependent process of surfactant 
secretion and P-selectin expression as well as thrombin-induced increases in 
permeability. In the case of thrombin-induced signaling, it is unclear which second 
messenger is being communicated to elicit these responses. As PAR-1 activation induces 
increases in IP3 and Ca2+, and Cx43 has been shown to facilitate the communication of 
both, in this study we chose to investigate which specific second messenger is being 
communicated in in situ pulmonary microvessels and is mediating the spatial expansion 
of thrombin-induced responses [89, 90, 99] 
 
 
Materials and Methods 
 
 
Fluorophores and Reagents 
 
The cell permeable Ca2+ indicators, Fura 2 AM (10 μM), Fluo 8 AM (20 μM), 
Fluo4 (10 μM), and the nuclear stain Hoeschst-33342 (10μg/ml) were from Tef Labs 
(Austin, TX). The F-actin marker CF488A-Phalloidin (0.5U/ml) was from Biotium 
(Hayward, CA). Thrombin (5-10 U/ml), rhodamine-dextran 70 kDa (RDx70; 0.5 mg/ml), 
rhodamine dextran 40kDa, (RDx40; 0.5 mg/ml) and fluorescein isothiocyate 20 kDa 
(FDx20; 0.5 mg/ml) were from Sigma (St. Louis, MO). The ER Ca2+-ATPase pump 
inhibitor, tert-butylhydroquinone (tBHQ; 10 μM) and ER IP3-receptor (IP3R) blocker, 
Xestospongin C (XeC; 25 μM) were from EMD Millipore (Billerica, MA). Cell 
permeable caged Ca2+ (NP-EGTA AM; 75 μM) and caged-IP3 (NPE-IP3; 2.5 mM) were 
from Invitrogen (Grand Island, NY). The transfection reagent, Chariot (1 mg/ml) was 
from Active Motif (Carlsbad, CA). The Cx43-gap junction inhibiting peptide, Gap27 
(190 μM) was custom synthesized by Genemed Synthesis (San Antonio, TX). 
Fluorophores and reagents were infused into microvessels in a Ca2+-rich HEPES-buffered 
Ringer’s solution (HBS; 150 mM Na+, 5 mM K+, 1 mM Ca2+, 1 mM Mg2+, 10 mM 
glucose, 20 mM HEPES) with 4% dextran (40 kDa) and 1% fetal bovine serum at a final 
pH of 7.4. Phosphate buffered saline with Ca2+ and Mg2+ was from GE Life Sciences. 
 
 
Isolated Perfused Lungs 
 
Animals were treated in accord with protocols approved by the Institutional 
Animal Care and Use Committee of the University of Tennessee Health Science Center. 
Animals were given ad libitum access to food and water, and placed on a 12-h light-dark 
cycle. Male Sprague-Dawley rats weighing 250-350g were purchased from a commercial 
vendor. Male endothelial specific-Cx43 knockout (EC-Cx43-/-) mice on a C57BL/6J 
background were bred in our animal facility, following the process previously reported 
[90, 100]. Age matched floxed Cx43 (Cx43fl/fl) mice were used as controls. Isolated 
blood-perfused lungs were prepared from rats and mice, as reported [101, 102]. Briefly, 
animals were anesthetized by intraperitoneal injection of ketamine and xylazine. Heparin 
was injected via cardiac puncture and the animals were exsanguinated. Cannulae were 
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inserted into the trachea, left atrium, and pulmonary artery to inflate and perfuse blood 
into the lungs, respectively. The lungs and heart were removed en bloc and transferred to 
the microscope stage. The lungs were constantly inflated and continuously pump-
perfused with warmed, autologous blood at 10ml/min (rat) and 2 ml/min (mouse). 
Pressures in the pulmonary artery, left atrium, and airway were maintained at 10, 3, and 5 
cm H2O, respectively. The lungs were kept moist with saline.  
 
For vascular delivery of fluorophores and agents into a microvessel network, a 
PE10 microcatheter was inserted through the left atrial cannula and wedged into a 
microvessel. An infusion of HBS was used to establish blood-free conditions in a small 
area of the lung. For delivery into single microvessels, a micropipette was filled with the 
appropriate agent and then attached to a pipette holder. A micromanipulator (MO-202U; 
Narishige, Japan) was used to guide the pipette holder to the vessel of interest, 
micropuncture the vessel, and then instill the agent or fluorophore. 
 
 
Ca2+ Imaging 
 
In a small region of rat lungs cleared of blood, Fura2 AM was infused into 
microvessels through the microcatheter for 30 minutes. After a 30 min HBS wash, the 
microvessels were excited at 340 and 380 nm. Fluorescence images were continuously 
captured at 515 nm either every 10 seconds or every 1 second, as indicated, using a 
microscope (BX61WI, Olympus) coupled to a high sensitivity camera [103]. Following a 
10-minute baseline fluorescence capture, we infused either 5 or 10 U of thrombin over 
10-15 minutes. Subsequently, the microvessels were flushed with HBS, followed by a 
second infusion of thrombin. For, blocking experiments, the inhibitor was infused 
following the wash-off of the first thrombin infusion. Endothelial cytosolic Ca2+ was 
determined using Fura2 340/380 emission ratio in 3 μm x 3 μm regions along the vessel 
wall for both venules and capillaries [103]. 
 
 
Actin Polymerization 
 
In a region of mouse lungs, cleared of blood using Ringer’s infusion, an alveolus 
near a target venule was filled with 2% Sudan black in oil by micropuncture and acted as 
a marker. The target venule was then micropunctured, and thrombin (5 U/ml) + RDx70 
(0.5mg/ml) was instilled over 10 minutes. RDx70 fluorescence was used to determine the 
spatial distribution of the instilled thrombin. Subsequently, the thrombin-treated and 
adjacent thrombin-free regions were fixed and permeabilized by superfusing the lung 
surface with 3.7% paraformaldehyde, followed by 0.05% Triton X-100, for 20 min each, 
respectively. The superfusion solutions were delivered via a PE10 microcatheter 
connected to an infusion pump (BSP-8000; Braintree Scientific, Braintree, MA). The 
superfusate flow rate was maintained at 10 μl/min. The microcatheter was positioned so 
that the opening was centered directly above the alveolus instilled with the Sudan Black 
marker. The spread of the superfusate over the lung surface was restricted via an opening 
cut in a plastic film placed over the lung surface. Following fixing and permeabilization, 
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the thrombin-treated and adjacent thrombin-free regions were superfused with blocking 
buffer containing 5% bovine serum albumin for 20 min. Finally, the region was treated 
with CF488A-phalloidin (0.5 U/ml) [104] and Hoeschst-33342 (10μg/ml) for 20 min to 
stain F-actin and nuclei, respectively. After a Ringer’s wash, the microvessels were 
imaged via a confocal microscope (Zeiss LSM710). In studies used to determine the role 
of Cx43, the experiments were repeated in EC-Cx43-/- mice. To inhibit IP3-dependent 
responses, XeC was infused for 30 minutes prior to thrombin instillation.  
 
During imaging, in addition to obtaining confocal images of the thrombin-
instilled region, images of the regions adjoining the thrombin-treated region were also 
captured. The images were captured in all directions extending away from the region of 
thrombin instillation. To reduce introduction of possible image artifacts by the lung 
curvature and possible change in image focus due to lung movement, a z-stack of images 
was captured at each x-y setting. Using this set of images, a montage, typically 1500 
microns x 1500 microns was stitched. In generating the montage, image sections with the 
best focus were selected from the z-stack of images. The use of different z-planes 
introduced small differences in fluorescence intensity along the entire length of the 
montage. CF488A-phalloidin fluorescence intensity was measured at randomly selected 
sites. The intensity measurements were obtained from the z-plane in which the 
measurement was in maximum focus. We typically quantified fluorescence intensity at 
more than 50 sites in each direction away from the thrombin-treated region for each 
experiment.  
 
 
Ca2+ and IP3 Uncaging 
 
We cleared a region of isolated rat lungs by infusing Ringer’s solution through a 
left atrial microcatheter. Then, we infused either Fluo4 AM or Fluo8 AM for 30 min. 
Subsequently, we either infused caged-Ca2+ (NP-EGTA) for 30 min or caged-IP3 (NPE-
IP3) + Chariot (1 mg/ml) for 30 min. Following a 30 min stabilization period, we 
captured images of microvessel Fluo8 or Fluo4 fluorescence (1 image/s) using the upright 
microscope (BX61WI). To uncage NP-EGTA or NPE-IP3, we exposed a defined region 
of the microvasculature to UV illumination (355 nm; 15 s) using a UV laser system 
(DPSL-355-30, RappOptoelectronic, Germany). Uncaging-induced responses in 
microvessels were captured for several minutes after exposure to the UV illumination.   
 
 
Microvascular Permeability 
 
In a region cleared of blood using a microcatheter in an isolated blood-perfused 
rat lung, a mixture of thrombin (5 U/ml) plus RDx70 (0.5 mg/ml) was instilled via 
micropuncture over 10 minutes. RDx70 fluorescence was used to determine the 
microvessel distribution of thrombin. After thrombin instillation, FDx20 was infused into 
the thrombin-instilled and adjacent microvessels via the microcatheter for one hour. An 
image of the FDx20 fluorescence in microvessels was taken every minute using an 
upright microscope (Olympus BX61WI). After one hour, FDx20 infusion was stopped 
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and replaced with HBS. Imaging was continued at one image per minute for 30 minutes. 
As reported, images were used to determine the FDx20 fluorescence at random sites both 
within and outside of the micropuncture instillation region [81]. The ratio of maximum 
FDx20 fluorescence during the FDx20 infusion (peak) to that after a 10 minute HBS 
wash (residual), termed ‘normalized fluorescence’ was used as an estimate of 
microvascular permeability at the measurement sites. 
 
Statistics 
 
All data are reported as mean±SEM. All multiple groups were compared with 
Kruskal-Wallis One Way ANOVA on Ranks followed by pair-wise multiple comparisons 
by Dunn’s method. Pairs of data were analyzed using rank-sum test. Significance was set 
at p<0.05. 
 
 
Results 
 
 
Induction of Microvascular Permeability by Thrombin 
 
Thrombin-induced increase in fluid permeability across endothelial monolayers is 
well established [84, 105, 106]. In contrast, the effect of thrombin on fluid flux across 
microvessels is not clear. To determine this, thrombin was continuously instilled into rat 
lung microvessels by micropuncture for 10 min (Figure 3-1A). Subsequently, 
permeability of single microvessels was determined using the FDx20 residual 
fluorescence method [81]. Images show that the residual FDx20 fluorescence was higher 
in thrombin-treated than in Ringer’s-treated microvessels (Figure 3-1B-E). Quantifying 
changes in single microvessels revealed that the normalized fluorescence was lower for 
thrombin-treated microvessels (Figure 3-1F). These results indicated that thrombin 
increased microvascular permeability in lung microvessels.  
 
 
Microvessel Actin Stress Fiber Formation 
 
In endothelial monolayers, thrombin-induced barrier perturbation occurs in 
tandem with cytoskeletal remodeling, which includes formation of actin stress fibers 
[107-109]. However, in in situ microvessels it is unclear whether thrombin-induced fluid 
flux is accompanied by actin stress fiber formation. To define this, a mixture of thrombin 
and RDx70 was continuously instilled for 10 min into microvessels of isolated blood-
perfused Cx43fl/fl mouse lungs using a micropipette. RDx70 helped identify the blood 
vessels to which the thrombin spread. Confocal images of RDx70 fluorescence captured 
during the infusion procedure suggested that thrombin spread from the micropunctured 
vessel into adjacent blood vessels, though the spread was restricted to microvessels  
  
 20 
 
 
Figure 3-1. Increases in microvessel permeability 
(A) Monochrome image shows vascular distribution of rhodamine fluorescence after 
instillation of thrombin (5 U/ml) + RDx70 (0.5 mg/ml) into a single microvessel of a rat 
lung. Note that the mixture distributed only to a small number of microvessels. Bar - 100 
μm (B, C) FDx20 (0.5 mg/ml) was infused into thrombin-treated microvessels for 60 min 
followed by a Ringer’s wash. Pseudocolored images show peak (B) and residual (C) 
fluorescence of FDx20 in the thrombin-treated vessels. Bar - 100 μm (D, E) 
Pseudocolored images show peak (D) and residual (E) FDx20 fluorescence in Ringer’s-
treated microvessels. Bar - 100 μm (F) Bar graph shows normalized FDx20 fluorescence 
quantified in single thrombin- and Ringer’s-treated microvessels. n=3 lungs for Ringer’s-
treated group, n=8 lungs for thrombin-treated group. *** = p < 0.001 compared to 
Ringer’s response.  
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located within 200 μm from the micropuncture site (Figure 3-2A). Thus, the instilled 
thrombin remained localized within a small number of microvessels. 
 
Fluorophore-tagged phalloidin is a marker for actin cytoskeleton in endothelial 
monolayers [110-112]. Hence, we utilized phalloidin tagged to the fluorophore CF488A 
to determine F-actin formation in in situ lung microvessels. Confocal images of untreated 
microvessels of Cx43fl/fl mouse lungs indicated that the CF488A fluorescence was low at 
baseline (Figure 3-2B). Images captured without labeling vessels with CF488A- 
phalloidin did not reveal any fluorescence, thus excluding the possibility that tissue 
autofluorescence contaminated CF488A fluorescence (Figure 3-2C). 
 
In response to instillation of PBS as vehicle control, the CF488A fluorescence in 
microvessels remained similar to that at baseline (Figure 3-2D). The fluorescence was 
similar in both the PBS-instilled vessels and those located outside the PBS-instilled 
region. Thus, the instillation procedure by itself did not modify F-actin magnitude in 
microvessels. In contrast, instillation of thrombin into microvessels resulted in a higher 
vascular CF488A fluorescence (Figure 3-2E). Montages of confocal images revealed 
that the CF488A fluorescence was high both in microvessels directly treated with 
thrombin and also in vessels located outside the thrombin-treatment region. The high 
fluorescence was evident even in microvessels located more than 1000 μm from the outer 
boundary of the thrombin-treated region (Figure 3-2E). However, in vessels located at 
increasing distances from the edge of the thrombin-instilled region, the fluorescence 
steadily declined to baseline levels (Figure 3-2E). Quantifying the CF488A fluorescence 
in thrombin-treated microvessels revealed that the fluorescence was 80% higher 
compared to baseline (Figure 3-2F). In addition, in microvessels located outside the 
thrombin-instilled region, the CF488A fluorescence was 60% higher compared to 
baseline. The data indicate an increase in F-actin both in microvessels treated with 
thrombin and in those located outside the thrombin-instilled region. Thus, thrombin 
increases F-actin even in microvessels spatially remote from those directly treated with 
thrombin. 
 
 
Microvessels Are the Source of Thrombin-Induced Responses 
 
Vascular instillations were used to define thrombin-mediated changes in 
endothelial permeability and F-actin. To exclude the possibility that observed responses 
were due to the instilled thrombin leaking into the alveolar compartment and initiating 
responses in epithelial cells, thrombin was instilled with RDx40, a fluorescence marker 
with a similar molecular weight as thrombin and thus, capable of closely following 
thrombin distribution spatially. Confocal images of RDx40 captured post-instillation 
indicated that its distribution was similar to that for RDx70 (Figure 3-3A). Moreover, 
CF488A-phalloidin fluorescence changes in response to vascular thrombin instillation 
was similar when either RDx70 or RDx40 was used as the marker (Figure 3-3B, E). In 
additional experiments, we determined the extent to which alveolar epithelial F-actin 
increased in response to thrombin. Toward this, we instilled together thrombin, RDx70, 
and the nuclear marker, Hoechst 33342 into alveoli. Subsequently, we instilled  
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Figure 3-2. Changes in F-actin formation in lung microvessels 
(A) Confocal image composite of rhodamine fluorescence shows the vascular distribution 
of thrombin (5 U/ml) + RDx70 mixture at the end of the instillation into a single 
microvessel (arrowhead) in Cx43fl/fl mouse lung. (B) Confocal image shows CF488A-
phalloidin fluorescence in untreated microvessels of a Cx43fl/fl mouse. Bar - 100 μm. (C) 
Image shows autofluorescence in microvessels of a Cx43fl/fl mouse captured at the same 
excitation and emission settings used for capturing CF488A-phalloidin fluorescence.  Bar 
- 100 μm. (D) A montage of confocal images shows CF488A-phalloidin fluorescence in 
lung microvessels of a Cx43fl/fl mouse after PBS instillation. Arrowhead - site of PBS 
instillation. Dashed line – outer boundary of PBS instillation. Bar - 100 μm. (E) Montage 
of confocal images shows CF488A-phalloidin fluorescence in Cx43fl/fl mouse lung 
microvessels located within and outside the thrombin-treated region. Arrowhead - site of 
thrombin instillation. Dashed line - outer boundary of thrombin-treated region. Bar - 500 
μm. (F) Graph shows CF488A-phalloidin fluorescence in microvessels for the various 
treatments indicated. ** = p < 0.01 compared to untreated response, †† = p < 0.01, ††† = 
p < 0.001, respectively compared to PBS response. Untreat - no instillation; PBS - PBS 
instillation; t5 - thrombin (5 U/ml) instillation; o μm - microvessels located within the 
thrombin-instilled region; 700 μm - microvessels located 700-1000 μm away from the 
outer edge of the thrombin- instilled region. # sites –number of measurement sites 
included in analysis. n=3 lungs for the un-instilled, n=3 for PBS-instilled and n=4 for 
thrombin- instilled groups. 
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Figure 3-3. Methodological controls for Thrombin-induced responses in lung 
microvessels 
(A) Confocal image composite shows distribution of rhodamine fluorescence in Cx43fl/fl 
mouse lung microvessels following instillation of thrombin (5 U/ml) + RDx40 mixture. 
Arrowhead - site of instillation. (B) Montage of confocal images show CF488A-
phalloidin fluorescence in microvessels following micropuncture instillation of thrombin 
(5 U/ml) + RDx40. White dashed line – outer boundary of the thrombin-instilled region. 
Arrowhead - site of instillation (C,D) Thrombin (5 U/mL), RDx70, and Hoechst 33342 
together were instilled into alveoli of Cx43fl/fl mouse lungs followed by instillation of 
3.7% paraformaldehyde into the same alveoli. Then the thrombin-treated region was 
superfused with CF488A-phalloidin, as detailed in Methods. Confocal image shows 
CF488A-phalloidin fluorescence alone in the thrombin-instilled region (C). Confocal 
image shows CF488A-phalloidin fluorescence with Hoechst 33342-stained nuclei (blue) 
(D). Note Hoechst 33342-stained nuclei represent cells treated with thrombin. Bars - 100 
μm. (E) Bar graph shows CF488A-phalloidin fluorescence following microvessel 
instillation of either thrombin + RDx40 (RDX40) or thrombin + RDx70 (RDX70). (F) 
Bar graph shows CF488A-phalloidin fluorescence at measurement sites in the absence of 
any treatment (untreat) or after alveolar instillation of thrombin (alv instill). # sites –
number of measurement sites included in analysis. n = 3 for both groups. 
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paraformaldehyde into the same alveoli, thus restricting the fixing process to the 
thrombin-treated alveoli. Finally, the thrombin-treated regions were superfused with 
CF488A-phalloidin. At the same imaging settings used for vascular thrombin instillation, 
the CF488A-phalloidin fluorescence in response to alveolar thrombin instillation was 
similar to that at baseline (Figure 3-3C, D, F). Moreover, the images revealed that the F-
actin levels were similar in both the thrombin-treated and -free alveoli. Taken together, 
these experiments suggest that the endothelium predominantly contributed to the 
observed responses to microvascular thrombin instillation. 
 
 
Lack of Endothelial Cx43 Limits Actin Stress Fiber Formation 
 
Interendothelial Cx43 gap junctions mediated P-selectin [80] expression and 
endothelial permeability in microvessels located spatially remote from the site of insult 
[81, 90]. To determine whether Cx43 gap junctions played a role in F-actin formation in 
microvessels located outside the thrombin-treated region, we instilled thrombin in lung 
microvessels of EC-Cx43-/- mice. Confocal images of CF488A-phalloidin fluorescence in 
microvessels of EC-Cx43-/- mouse lungs at baseline reveal that the fluorescence was 
similar to that in Cx43fl/fl mouse lung microvessels at baseline. (Figure 3-4A). Further, 
the images also show that thrombin treatment resulted in only a small increase of 
CF488A-phalloidin fluorescence in EC-Cx43-/- mouse lungs (Figure 3-4B). 
 
Quantifying CF488A fluorescence in single microvessels revealed that in EC-
Cx43-/- mice, thrombin instillation resulted in a 20%, but insignificant, increase in the 
fluorescence compared to that in Ringer’s-instilled microvessels (Figure 3-4C).  
Moreover, in microvessels located outside the thrombin-treated region, the CF488A 
fluorescence remained at baseline levels. This lack of increase in CF488A fluorescence 
was in direct contrast to that observed in Cx43fl/fl mouse lung microvessels. Thus, the data 
suggest that the thrombin-induced increase in F-actin in microvessels was blunted in the 
absence of endothelial Cx43. 
 
 
Inhibiting Endothelial ER Ca2+ Release Limits Actin Stress Fiber Formation   
 
Thrombin causes release of Ca2+ from ER stores, which has been indicated to 
underlie F-actin formation in endothelial monolayers [98, 113, 114]. Hence, we 
determined whether the increase in F-actin in mouse lung microvessels was dependent on 
ER store Ca2+ release. Toward this, ER Ca2+ release was inhibited using XeC, an 
established inhibitor of IP3R on ER [103, 115, 116]. XeC was infused into microvessels 
in a small region of Cx43fl/fl mouse lungs via a venous microcatheter. Subsequently, 
thrombin was instilled by micropuncture into a subset of XeC-treated microvessels. XeC-
pretreatment blunted the thrombin-induced increase in CF488A-phalloidin fluorescence 
(Figure 3-5A, B). The blunting was evident in all microvessels within the XeC-treated 
region (Figure 3-5C). Thus, the data indicate that IP3-dependent ER store Ca2+ release 
mediated the thrombin-induced microvessel F-actin formation in both the thrombin-
treated and -free regions.  
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Figure 3-4. Effect of endothelial Cx43 on F-actin formation 
Thrombin (5 U/ml) or PBS was instilled into microvessels in a focal region of lungs from 
EC-Cx43-/- mice. (A) Confocal image composite shows CF488A-phalloidin fluorescence 
following PBS instillation. (B) Montage of confocal images show CF488A-phalloidin 
fluorescence following thrombin instillation. Arrowheads - site of PBS or thrombin 
instillation. Dashed line - outer boundary of thrombin-treated region. Bars - 100 μm.  (C) 
Bar graph shows CF488A-phalloidin fluorescence normalized to baseline levels in 
microvessels within and outside (at indicated distances away) the thrombin-instilled 
region. Data from microvessels of Cx43fl/fl mice shown for comparison (white bars). # 
sites –number of measurement sites included in analysis. n = 4 lungs per treatment group.  
* = p < 0.05, *** = p < 0.001, compared to data from thrombin-instilled microvessels of 
Cx43fl/fl mice.  
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Figure 3-5. Effect of IP3R inhibition on F-actin formation 
ER IP3R inhibitor, XeC (25 μM) or Ringer’s was infused into lung microvessels of 
Cx43fl/fl mice followed by instillation of PBS or thrombin (5 U/ml) into a small subset of 
XeC-treated microvessels. (A) Confocal image composite shows CF488A-phalloidin 
fluorescence in Ringer’s pretreated and PBS-instilled microvessels.  (B) Montage of 
confocal images show CF488A-phalloidin fluorescence in XeC pretreated and thrombin-
instilled microvessels. Arrowheads - site of instillation. Dashed line - outer boundary of 
thrombin-treated region. Bars - 100 μm. (C) Bar graph shows CF488A-phalloidin 
fluorescence normalized to baseline levels in microvessels within and outside (at 
indicated distances away) the thrombin-instilled region. Black and white bars show data 
from XeC- and Ringer’s-pretreated microvessels, respectively. # sites –number of 
measurement sites included in analysis. n = 4 lungs per treatment group. ** = p < 0.01, 
*** = p < 0.001, compared to data from Ringer’s-pretreated thrombin-instilled 
microvessels.  
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IP3 Mediates the Spatially Extensive Actin Stress Fiber Formation 
 
Gap junctions facilitate the intercellular transfer of both Ca2+ and IP3 [89, 90]. 
Thus, interendothelial diffusion of either IP3 or Ca2+ from the thrombin-treated 
microvessels could have caused the increase in F-actin in microvessels located outside 
the thrombin-treated region. Hence to define the specific second messenger involved, we 
instilled XeC into microvessels in a small lung region of Cx43fl/fl mice, followed by 
instillation of thrombin into an adjacent region that overlapped the XeC-treatment region 
(Figure 3-6B). Labeling microvessels with CF488A-phalloidin revealed that the 
fluorescence was low in the XeC-instilled microvessels, but high everywhere else. 
Quantifying the response revealed that CF488A-phalloidin fluorescence remained at 
baseline levels only in the XeC-treated microvessels (Figure 3-6C). Thus, the data 
clearly indicate that thrombin-induced increase in F-actin was evident in the XeC-free, 
but absent in the XeC-treated regions. In contrast, when XeC was replaced with PBS, the 
thrombin-induced increase in CF488A fluorescence was evident in all microvessels, 
including those instilled with PBS (Figure 3-6A, C). These data suggest that the 
thrombin-induced response was blunted only in microvessels pretreated with XeC. 
Together the results suggest that IP3, but not Ca2+, was the second messenger mediating 
the thrombin-induced spatially extensive responses in microvessels. 
 
 
Thrombin Increases the Magnitude of ER-Dependent Ca2+ Oscillation in Lung 
Microvessels  
 
In endothelial monolayers, thrombin induces IP3-dependent release of ER store 
Ca2+, which increases mean endothelial cytosolic Ca2+ [112-114]. However, the 
characteristic of the thrombin-induced Ca2+ response in lung microvessels is not clear. 
Emerging discussion suggests differences in signaling between lung microvessels and 
lung microvascular endothelial cells in culture [84]. Thus, we hypothesized that Ca2+ 
responses to thrombin in microvessels may differ from that reported in endothelial 
monolayers. To test this, we infused thrombin into microvessels of isolated blood-
perfused rat lungs loaded with Fura2 AM. Changes in the ratio of Fura2 fluorescence at 
340 and 380 nm excitation indicated that thrombin infusion increased Ca2+ levels in lung 
microvessels (Figure 3-7A-D). Quantifying the Ca2+ response over the duration of the 
experiment, as reported [103], indicated that thrombin increased the magnitude of 
cytosolic Ca2+ oscillations in lung microvessels (Figure 3-7F). Infusing thrombin into the 
same microvessels for a second time duplicated the Ca2+ response (Figure 3-7F).  
 
To determine the Ca2+ source, the experiments were repeated after treating 
microvessels with XeC. XeC pretreatment blunted the thrombin-induced increase in 
oscillation amplitude (Figure 3-7E, G). Quantifying the amplitude of Ca2+ oscillations 
indicated a concentration-dependent response to thrombin (Figure 3-7H). XeC and 
tBHQ, an inhibitor of ER Ca2+-ATPase pumps [117], both blunted the increase in Ca2+ 
oscillation amplitude (Figure 3-7I). Together, the data suggest that thrombin increases 
IP3-mediated ER Ca2+ release leading to increases in the magnitude of cytosolic Ca2+ 
oscillations in lung microvessels.  
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Figure 3-6. Effect of focal IP3R inhibition in lung microvessels of Cx43fl/fl mice 
(A) Montage of confocal images show CF488A-phalloidin fluorescence in microvessels 
following separate intravascular instillation of thrombin (5 U/ml; white outline) and PBS 
(yellow outline) into overlapping regions. Bar - 100 μm. (B) Montage of confocal images 
showing CF488A-phalloidin fluorescence in microvessels following separate 
intravascular instillation of thrombin (5 U/ml; white outline) and XeC (25 μM; red 
outline) into overlapping regions. Bar - 100 μm. (C) Bar graph compares CF488A-
phalloidin fluorescence in single microvessels located in the various regions as indicated. 
PBS in - within PBS-instillation region; XeC in - within XeC-instillation region; PBS out 
- outside PBS- and thrombin-instillation regions; XeC out - outside XeC- and thrombin-
instillation regions. Average fluorescence of microvessels within the thrombin-instilled 
region was used to normalize the fluorescence data of other regions. * = p < 0.05, *** = p 
< 0.001 compared to XeC in, respectively. # sites –number of measurement sites included 
in analysis. n = 4 lungs per treatment group. 
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Figure 3-7. Thrombin-induced Ca2+ responses in lung microvessels 
(A-E) Pseudocolored images show fluorescence due to excitation at 340 and 380 nm in 
Fura2 AM loaded rat lung microvessels (A-B), the ratio of the fluorescence at 340 and 
380 at baseline (C), during thrombin (10U/ml) infusion (D) and during thrombin (10 
U/ml) infusion after pretreatment with XeC (25 μM) (E). Bar - 10 μm. (F) Tracings show 
temporal changes in the Fura2 AM fluorescence ratio (F340/F380) in response to a dual 
infusion of thrombin (10U/ml) into lung microvessels. Each thrombin infusion was 
preceded by a Ringer’s infusion to determine baseline F340/F380 values. t10 – thrombin 
(10 U/ml), hbs – Ringer’s. (G) Tracings show temporal changes in F340/F380 in 
response to an infusion into microvessels of thrombin (10 U/ml) followed by XeC (25 
μM) pretreatment and then another thrombin (10 U/ml) infusion. t10 – thrombin (10 
U/ml), hbs – Ringer’s, xec - XeC. (H) Bar graph shows the amplitude of Ca2+ oscillations 
in lung microvessels in response to infusions of 5 and 10 U/ml of thrombin. t-5 – 
thrombin (5 U/ml), t-10 – thrombin (10 U/ml). †† = p < 0.01 compared to baseline; ‡‡ = 
p < 0.01 compared to 5 U thrombin treatment. n = 4 lungs per treatment group. (I) Bar 
graph shows the % change in amplitude of Ca2+ oscillations in lung microvessels in 
response to the indicated treatments. * = p < 0.05 compared to thrombin alone treatment 
at the respective concentration. n=4 lungs per treatment group. 
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The present data that thrombin increases the amplitude of Ca2+ oscillations in 
microvessels contrasts with reported data showing increase in mean Ca2+ concentration in 
endothelial monolayers [118]. Hence to exclude the possibility that the absence of a mean 
Ca2+ increase in the present study was an artifact of the imaging system, we co-loaded rat 
lung microvessels with the Ca2+ cage, NP-EGTA and the Ca2+ indicator, Fluo 8, as 
reported [90]. A brief exposure to a 355 nm UV beam increased mean endothelial 
cytosolic Ca2+ above baseline (Figure 3-8A-C) both at the site of uncaging and adjoining 
microvessels. The uncaging-induced Ca2+ increase suggests that the imaging system 
captured increases in mean cytosolic Ca2+. Thus, we interpret that the predominant 
response to thrombin in microvessels was an increase in cytosolic Ca2+ oscillation 
magnitude. 
 
 
Focal Release of Caged-IP3 Induces Cx43-Dependent Ca2+ Responses in Adjacent 
Microvessels 
 
In the lung microvascular network, Cx43-dependent mechanisms mediated the 
spread of Ca2+ in response to release of Ca2+ at a focal site [90]. Hence, to determine 
whether IP3 released focally will also spread similarly, we co-loaded NPE-IP3 and Fluo4 
into rat lung microvessels, and then exposed the microvessels to the 355 nm UV beam. 
UV uncaging caused a progressive increase in Fluo4 fluorescence at both the uncaging 
site and in adjoining microvessels (Figure 3-9A). Thus, IP3 release at a focal site, 
increased Ca2+ in microvessels spatially away from the uncaging site. At longer time 
periods post-uncaging, the Ca2+ response declined to baseline levels. Further, the increase 
in Ca2+ was highest at the site of uncaging and progressively declined at sites further 
away from the uncaging site (Figure 3-9B). To determine the role of Cx43 in the 
induction of responses in the spatially remote microvessels, we pretreated microvessels 
with the Cx43-gap junction inhibitor, Gap27 [81] and then uncaged IP3. Gap27 
completely blocked the Fluo4 fluorescence increase in microvessels located outside the 
uncaging region, but not within it (Figure 3-9A, C). Thus, release of IP3 at focal sites by 
uncaging, spreads to adjacent microvessels and initiated responses in a Cx43-dependent 
manner. 
 
 
Thrombin Mediates Spatially Extensive Increases in Microvessel Permeability 
 
Since thrombin instillation increased F-actin in microvessels outside the 
thrombin-treated region, we determined whether fluid permeability was also altered in 
these microvessels. Toward this, thrombin was instilled into microvessels in a focal 
region of rat lungs followed by FDx20 infusion into both the thrombin-treated and 
thrombin-free neighboring regions. Images indicated that the residual fluorescence of 
FDx20 was higher in both the thrombin-treated and –free microvessels compared to 
Ringer’s-treated microvessels (Figure 3-10A-D). However infusion of Gap27 prior to 
thrombin instillation restricted the high residual fluorescence to microvessels directly 
treated with thrombin (Figure 3-10E, F). Quantifying the normalized fluorescence 
revealed that thrombin increased permeability in microvessels located several hundred  
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Figure 3-8. Ca2+ uncaging in lung microvessels 
(A,B) Pseudocolored images show the Fluo 8 fluorescence in rat lung microvessels co-
loaded with NP-EGTA (75 μM) and Fluo 8 before (A) and after (B) UV uncaging of NP-
EGTA. Circle – site of uncaging. Bar - 10 μm (C) Bar graph shows spatial changes in 
Fluo8 fluorescence in response to uncaging NP-EGTA. * = p < 0.05 compared to 0 μm. n 
= 4 lungs. 
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Figure 3-9. IP3 uncaging in lung microvessels 
(A) Pseudocolored images show response to uncaging NPE-IP3 in rat lung microvessels 
co-loaded with NPE-IP3 (2.5 μM) and Fluo4. NPE-IP3 was loaded into microvessels 
using Chariot, as detailed in Methods. Images show control response in the absence of the 
Cx43 gap junction inhibitor, Gap27 (top row), during infusion of Gap27 (middle), and 
after wash-off of the Ga27 (bottom). Circle – site of uncaging. Bar - 20 μm. (B) Bar 
graph shows NPE-IP3 uncaging-induced changes in Fluo4 fluorescence at increasing 
distance from the uncaging site. ‡p < 0.05 compared to 0 μm. n = 3 lungs. (C) Bar graph 
shows comparison of the spatial decay of Fluo4 fluorescence in response to IP3 uncaging 
in the presence of Gap27 and after washout of Gap27. (B,C) * = p < 0.05 compared to 0 
μm. n = 3 lungs.  
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Figure 3-10. Effect of inhibiting intercellular communication on microvessel 
permeability 
PBS or thrombin (5 U/ml; 10 min) was instilled into microvessels in a focal region of a 
rat lung. Subsequently, FDx20 was infused into microvessels followed by a Ringer’s 
wash, as detailed in Methods. (A, B) Images show peak (A) and post-wash (B) FDx20 
fluorescence in PBS-treated microvessels. Dashed line - outer boundary of microvessels 
instilled with PBS. Bar - 100 μm. (C, D) Images show peak (A) and post-wash (B) 
FDx20 fluorescence in thrombin-treated microvessels. Dashed line - outer boundary of 
microvessels instilled with thrombin. Bar - 100 μm. (E, F) Gap27 was infused into 
microvessels in a small region of a rat lung for 45 min. followed by instillation of 
thrombin into subset of the Gap27-treated vessels. FDx20 was then infused into the 
Gap27-treated vessels followed by a Ringer’s wash. Images show peak (E) and post-wash 
(F) FDx20 fluorescence in microvessels. Dashed line - outer boundary of microvessels 
instilled with thrombin. Bar - 100 μm. (G) Graph shows normalized fluorescence in 
single microvessels both within (0 μm) and outside the treatment regions at distances as 
indicated. *** = p < 0.001 compared to Ringer’s treatment at same indicated distance. † 
= p < 0.05, ††† = p < 0.001 compared to Gap27+thrombin at same indicated distance. 
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microns away from the outer edge of the thrombin-treated region (Figure 3-10G). The 
spatially extensive increase was blunted in Gap27-treated microvessels. Together the data 
suggested that thrombin causes Cx43-dependent hyperpermeability in lung microvessels. 
 
 
Discussion 
 
In this study, we show for the first time that the receptor-mediated agonist 
thrombin initiates spatially extensive responses in microvessels via interendothelial 
diffusion of IP3. Moreover, the experiments reveal that the diffusion is facilitated by 
Cx43 gap junctions. Together the present data reveal a novel relationship wherein Cx43 
and IP3 act in tandem to expand the ambit of thrombin-induced responses in lung 
microvessels. Finally, the data suggests that signaling resulting from compartmental 
increases in second messengers elicited by activation of plasma membrane receptors 
differs from that generated by global cell-wide increases in second messengers elicited by 
photolytic uncaging.  
 
Utilizing focal instillations of thrombin into lung microvessels, we provide the 
first evidence that IP3 increases F-actin in thrombin-treated and –free microvessels. The 
present finding that IP3 increases F-actin in microvessels directly treated with thrombin is 
in agreement with the reported data on thrombin-mediated responses in endothelial 
monolayers [108, 119-122]. However, the finding that IP3 increases F-actin in 
microvessels located in adjacent thrombin-free regions is hereto unknown.  
 
In addition to IP3, thrombin also increases Ca2+, cAMP and ATP levels in 
endothelial monolayers [92, 123, 124]. Thus, any of these diffusible second messengers 
could have mediated the cytosolic Ca2+ response in the spatially remote thrombin-free 
microvessels. ATP is released by endothelial cells via pannexins and connexin-
hemichannels on the luminal membrane, and acts on purinergic receptors of adjacent 
cells [92, 125]. The luminal ATP release suggests that its actions would be evident in 
endothelial cells downstream from the stimulus site. In the present study, the responses in 
the thrombin-free regions were independent of blood-flow direction, thus excluding ATP 
as the diffusing messenger. Thrombin induces a temporally delayed increase in cAMP 
[124, 126], which signals through non-ER pathways. ER inhibition blocked the spatially 
remote responses, thus, excluding cAMP as the diffusing messenger. XeC blocked IP3 
receptors and thus, Ca2+ release, thereby preventing the establishment of either IP3 or 
Ca2+ as the diffusible second messenger using global XeC treatment. Separate 
instillations of XeC and thrombin into focal, yet intersecting regions, solved this 
conundrum. In the thrombin-instilled region, neither IP3 nor ER Ca2+ release was 
blocked.  Hence, both second messengers were free to diffuse interendothelially into the 
thrombin-free microvessels, including microvessels in the XeC-instilled region. If Ca2+ 
had been the diffusible second messenger, then increased F-actin would have been 
evident even in the XeC-treated region.  However, no increase in F-actin was evident in 
microvessels in the XeC-treated region. This lack of a response only in the XeC-treated 
region implicated IP3 as the diffusible messenger mediating the spatially extensive 
responses from the thrombin-treated to the thrombin-free microvessels. 
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The present experiments show that in lung microvessels, thrombin increased the 
amplitude of endothelial cytosolic Ca2+ oscillations via ER Ca2+ release. In endothelial 
monolayers, thrombin also induces ER Ca2+ release [110, 113, 114, 119]. However, the 
ER Ca2+ release increases the mean endothelial cytosolic Ca2+ concentration. Thus, the 
present data in microvessels stand in contrast to that from endothelial cells. The 
difference in Ca2+ response could point to differences in signaling between endothelial 
cells in situ and in culture. We previously noted that LPS-induced Ca2+ responses in 
microvessels were different from those in endothelial monolayers [103]. Moreover, it has 
recently been highlighted that thrombin activates different signaling pathways in these 
two experimental models [84]. Further, the thrombin-induced Ca2+ responses may be 
concentration dependent. Thus, the present data suggest that thrombin mediated 
responses are dependent on the experimental model used and hence, should be viewed 
from that context.  
 
The current finding that IP3 is the diffusible messenger mediating thrombin-
induced responses among endothelial cells suggests that IP3-dependent Ca2+ release 
mediates the F-actin increases in both thrombin-treated and –free cells. IP3-dependent ER 
store Ca2+ release concomitantly increases activation of p38 mitogen-activated protein 
kinase (p38-MAPK) [127-130]. However, the relationship between store Ca2+ release and 
p38-MAPK activation is cell-type- and agonist-dependent. In endothelial cells, LPS 
increases activation of p38-MAPK[131]. We reported that LPS causes store Ca2+ release 
in lung microvessels [103]. Thus, it is possible that the thrombin-induced store Ca2+ 
release activated p38-MAPK. Activated p38-MAPK phosphorylates the actin-binding 
protein, heat-shock protein 27 (HSP27) in endothelial and other cells via MAP kinase-
activated protein kinase 2 (MAPKAP kinase 2) [130-134]. Phosphorylation of HSP27 
facilitates F-actin polymerization and stress fiber formation [135-137]. Thus, activated 
p38-MAPK could increase F-actin levels via phosphorylation of HSP27 in endothelial 
cells. However, this pathway requires further delineation in lung microvessels. Moreover, 
other factors such as RhoA have been implicated in actin dynamics [138] and may 
modulate F-actin levels either separately or in tandem with the p38-MAPK pathway. 
Thus, the specific pathway and associated proteins involved in store Ca2+ release-
dependent F-actin increase in lung microvessels require further consideration. 
 
Endothelial connexins play a role in the induction of P-selectin, endothelial 
permeability, and hypoxic arteriolar vasoconstriction in spatially remote microvessels 
[90, 94, 139]. While both Cx43 and Cx40 have been shown to mediate the above 
responses, the knockout mice experiments exclude a role for Cx40 in the present study. 
The photolytic uncaging experiments add further support for Cx43 as mediating the 
interendothelial diffusion of IP3 in the lung microvascular network. Cx43 supports the 
diffusion of IP3 in astrocytes [88] and endothelial monolayers [89]. The present 
observations concur with these previous reports. Thus, Cx43 is the predominant connexin 
mediating thrombin-induced responses in microvessels. 
 
In Cx43fl/fl mice, F-actin increased in microvessels in direct contact with 
thrombin. However, the increase was smaller in microvessels of EC-Cx43-/- mice. This 
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difference is intriguing because the microvessels in both mouse types were exposed to the 
same concentration of thrombin and for the same duration. Thus, it is likely that Cx43 
also contributed to signaling differences in thrombin-treated microvessels. Studies by 
Bhattacharya’s group and others have suggested that in lung microvessels, pro-
inflammatory responses are heterogeneous among endothelial cells [139-141]. Thus, 
some endothelial cells termed pacemakers may initiate the responses that then propagate 
to neighboring cells via interendothelial communication [139, 142]. Based on this, we 
propose that thrombin-induced-IP3 release and downstream signaling may be 
heterogeneous in lung microvessels. The heterogeneity may be attributed to endothelial 
differences in thrombin receptor density or other factors involved in the signaling. 
Indeed, heterogeneity in the distribution of thrombin receptors among microvessels has 
been reported [143]. Thus, those endothelial cells with a higher receptor density may act 
as pacemakers. The higher levels of IP3 generated by the pacemaker could diffuse to 
adjacent endothelial cells along the microvessel and increase the overall response in the 
entire vessel. In the absence of interendothelial communication, this transfer of IP3 may 
be blocked and thus the overall microvessel response to thrombin may be mitigated. 
However, the establishment of this or other possible mechanisms as the specific factors 
responsible for reduction in thrombin-induced endothelial response in EC-Cx43-/- mice 
requires further elucidation. 
 
In addition to the smaller thrombin-induced increases, the baseline F-actin 
fluorescence was in itself lower in EC-Cx43-/- mice. This difference could be due to 
interaction of Cx43 with the actin cytoskeleton. Cx43 interaction with the actin 
cytoskeleton is reported in several cell types, including brain endothelium, astrocytes and 
B-cells [144-148]. Thus, it is possible that reduction in Cx43 expression lowers Cx43-F-
actin interaction, likely through modifying the interactions among proteins in the Cx43 
interactome. For example, reduction in Cx43-ZO1 interaction reduced F-actin levels in 
brain endothelial cells [144]. Accordingly, it is possible that in the EC-Cx43-/- mice, the 
lack of Cx43 may have resulted in the loss of interaction among proteins in the Cx43 
interactome, and thus resulted in the reduced F-actin levels. The specific proteins 
involved in this interaction and the signaling involved behind the reduction in F-actin 
levels will require further elucidation.  
 
The current study indicates that activation of plasma membrane receptors induces 
IP3-mediated spatial expansion of pro-inflammatory responses. In contrast, increase in 
cell-wide Ca2+ by photolytic uncaging of Ca2+ induces Ca2+-diffusion-mediated spatial 
expansion of responses [90]. Thus, signal compartmentalization associated with 
activation of plasma membrane receptors likely defines the specific second messenger 
that diffuses through the gap junctions. Since thrombin activates G protein-coupled 
receptors [50], IP3 is generated closer to the plasma membrane, and thus in proximity to 
gap junctions. This proximity likely facilities IP3 diffusion through the gap junctions. 
This argument is further supported by the smaller spatial spread of the response 
associated with IP3 uncaging. As uncaging increased IP3 in a cell-wide manner, relatively 
low levels of IP3 would be available at the cell-cell junction and thus for diffusion via gap 
junctions. This would limit the ambit of responses to IP3 uncaging, but not for receptor-
mediated IP3 increase. While IP3 also triggers ER store Ca2+ release, the inherent 
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compartmentalization of Ca2+ due to the steep decline in its concentration from the 
release site [149] may also limit its availability in the vicinity of gap junctions. In 
addition, in the present study, the cellular Ca2+ response was an increase in the magnitude 
of cytosolic Ca2+ oscillations, rather than an increase in mean cytosolic Ca2+ 
concentration. This difference in Ca2+ response may underlie the preclusion of Ca2+ 
diffusion via gap junctions, and needs explored further. Whether these interpretations of 
spatial compartmentalization is applicable to other pro-inflammatory mediators that 
induce interendothelial signaling also remains to be elucidated.   
 
In conclusion, our studies here showed that IP3 generated in response to thrombin 
is the specific second messenger mediating the thrombin-induced responses of increased 
F-actin formation and permeability in the pulmonary microvasculature, and that the 
interendothelial communication of IP3 via Cx43 mediates the spatial expansion of these 
responses. Our experiments also demonstrated that the origin of the second messenger, as 
determined by the stimulus, defines both the breadth and the type of response observed. 
Our work here highlights the differences between inflammatory signaling observed in 
culture and in in situ. Further investigations utilizing more physiologically-relevant in 
situ preparations may reveal strategies that limit these expansive inflammatory responses 
through the targeted blocking of interendothelial communication. 
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CHAPTER 4.    COOPERATIVE SIGNALING OF THROMBIN AND S1P2 IN 
BARRIER DYSFUNCTION 
 
 
Introduction 
 
S1P is a lysophospholipid signaling molecule that acts through G-protein coupled 
receptors on endothelial cells to mediate various cellular activities, including 
microvascular permeability [9, 62, 67]. While signaling through the primary receptor 
S1P1 is barrier-protective, signaling through S1P2 has been found to be barrier-disruptive 
[4, 68, 69]. The expression of both S1P and the receptor S1P2 has been shown to be 
increased in inflammation [62, 65, 70]. In HMVEC monolayers, inflammatory mediators 
LPS and TNFα were shown to induce increases in both S1P2 mRNA and protein, and 
blocking S1P2 signaling in these cells blocked the LPS- and TNFα-induced increases in 
barrier permeability [70]. In addition, in isolated perfused rat lungs, it was found that 
blocking S1P2 signaling also blocked in the induction of lung edema and increased 
permeability by hydrogen peroxide [69] While S1P2 signaling displays a clear link to 
hyperpermeability in the context of inflammatory mediators, little has been shown on 
direct effects in lung microvessels. 
 
The inflammatory mediator thrombin activates the receptor PAR-1, and activation 
of PAR-1 has been shown to activate SphK1 and induce local increases in S1P [62, 63, 
67]. In fact, in endothelial monolayers, it has been indicated that this increase may 
mediate the thrombin-induced hyperpermeability [150]. In addition, the inhibition of 
SphK1 in endothelial cells also inhibits the thrombin-induced increases in cytokine 
production and secretion [63]. Both PAR-1 and S1P2 activation is mediated by the G-
proteins Gαi, Gαq, and Gα12/13, leading to calcium store release, RhoA activation, and 
subsequent increases in permeability [61, 69, 98, 151-154]. While the dual activation of 
these receptors may lead to a cooperative effort in inflammation, it is unknown the extent 
to which S1P2 signaling may actually participate in or contribute to thrombin-induced 
signaling within lung microvessels. Further, though other inflammatory mediators may 
affect S1P2 expression, it is unknown whether thrombin may have a similar effect, 
specifically within pulmonary microvascular endothelium.  
 
To explore the possible role of S1P2-directed signaling in lung inflammation, we 
studied changes in S1P2 expression in pulmonary microvascular endothelial cells and 
microvessels induced by the inflammatory mediator thrombin in addition to exploring 
S1P2 signaling in the context of thrombin-induced endothelial hyperpermeability.  As the 
gap junction channel protein Cx43 has been shown to mediate thrombin-induced spatially 
extensive responses, we investigated thrombin-induced changes in S1P2 in both our 
Cx43fl/fl and EC-Cx43-/- mouse lines [155]. Our results show that thrombin is able to 
induce an increase in S1P2 expression in primary mouse pulmonary microvascular 
endothelial cells (PMVECs) as well as pulmonary microvessels in Cx43fl/fl and EC-Cx43-
/- mouse lungs. Interestingly, while the increase in expression was nominal and confined 
to the thrombin-treated area in our EC-Cx43-/- mouse line, in the Cx43fl/fl mouse lungs 
thrombin induced a significant increase in the treated area and an even greater increase 
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outside of the treated microvessels. To further investigate this unique pattern of 
thrombin-induced effects, we also looked at ROS generation following thrombin 
treatment. Similar to S1P2 expression, we found that thrombin induced a greater increase 
in ROS outside of the treatment area than inside in the Cx43fl/fl mouse lungs. Finally, to 
study contributions of S1P2 signaling in thrombin-induced increases in microvascular 
permeability, we pretreated microvessels with the S1P2 antagonist JTE-013. We found 
that blocking S1P2 signaling effectively blocked thrombin-induced increases in ROS 
generation as well as hyperpermeability. Our results show that in pro-inflammatory 
signaling, thrombin may induce increased presence of S1P2 in pulmonary microvascular 
endothelial cells in a manner mediated by gap junctional communication, and signaling 
following S1P2 activation contributes to thrombin-induced effects in the 
microvasculature. 
 
 
Materials and Methods 
 
 
Animals 
 
All mouse studies were approved by the Institutional Animal Care and Use 
Committee of the University of Tennessee Health Science Center. Endothelial specific-
Cx43 knockout (EC-Cx43-/-) mice on a C57BL/6J background were bred in our animal 
facility as previously reported [90, 100, 155], and age-matched floxed Cx43 (Cx43fl/fl) 
mice were used as controls. Mice were given access to food and water ad libitum, and 
placed on a 12 h light-dark cycle. 
 
 
Fluorophores and Reagents 
 
Thrombin (10 U/mL), sphingosine-1-phosphate (S1P; 10 μM), fluorescein 
isothiocynate 20 kDa (FDx20; 0.5 mg/mL), rhodamine-dextran 70 kDa (RDx70; 0.5 
mg/mL), and N-acetyl cysteine (NAC; 5 μM) were from SigmaAldrich (St. Louis, MO). 
The nuclear marker Hoeschst-33342 (10 μg/mL) was from Teflabs (Austin, TX). The cell 
permeable dye Calcein AM (1.25 μM) was from Invitrogen (Carlsbad, CA). The S1P2 
receptor antagonist JTE-013 (1 μM) was from Cayman Chemical. Collagenase Type II 
(10 mg/mL) was obtained from Worthington Biochemical (Lakewood, NJ). The 
fluorescent reactive oxygen species indicator CellROX deep red reagent (15 μM) was 
from ThermoFisher (Waltham, MA). The anti-S1P2 Antibody (5-10 μg/mL) came from 
MilliporeSigma (Billerica, MA). The CF488A-conjugated goat anti-mouse secondary 
antibody (1 μL/mL) was from Biotium (Hayward, California). Fluorophores and reagents 
were infused into pulmonary microvessels in a Ca2+-rich HEPES-buffered Ringer’s 
solution (HBS; 150 mM Na+, 5 mM K+, 1 mM Ca2+, 1 mM Mg2+, 10 mM glucose, 20 
mM HEPES) with 4% dextran (40 kDa) and 1% fetal bovine serum at a final pH of 7.4. 
Phosphate buffered saline with Ca2+ and Mg2+ (PBS) was from GE Life Sciences 
(Pittsburg, PA). 
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Lung Preparation 
 
Isolated perfused lungs were prepared from mice as reported [155]. Adult mice 
were anesthetized by intraperitoneal injection of ketamine and xylazine, exsanguinated 
via cardiac puncture, and the blood was collected in heparin. The chest cavity was 
opened, and cannulae were placed in the trachea, pulmonary artery, and left atrium. The 
lungs and heart were excised en bloc, and moved to the microscope stage. Through the 
tracheal cannula the lungs were constantly inflated with room air at a pressure of 5 cm 
H2O. The lungs were constantly pump-perfused at a rate of 2 mL/min, and pressures in 
the pulmonary artery cannula and left atrial cannula were maintained at 10 and 3 cm H2O, 
respectively. 
 
 
S1P2 Expression in PMVECs 
 
Mouse lung microvascular endothelial cells were isolated from Cx43fl/fl and EC-
Cx43-/- lungs by collagenase II digestion and cultured overnight at 37°C in medium 199 
supplemented with growth factors on fibronectin-coated coverslips. The following day, 
coverslips were treated with thrombin (10U/mL) for 10 minutes (or no treatment in the 
case of control). The coverslips were washed three times with PBS and then fixed for 10 
minutes with 3.7% paraformaldehyde. The cells were then again washed thrice with PBS 
and then permeabilized with 0.05% Triton X for 10 minutes. They were washed 3 more 
times with PBS and then blocked using 5% bovine serum albumin for 1 hour. The cells 
were then incubated overnight at 4°C with anti-S1P2 monoclonal Ab (5 μg/mL). The 
next morning, the cells were again washed 3 times with PBS then incubated for 1 hour 
with CF488A-conjugated secondary antibody (1 μL/mL) and a nuclear stain (Hoeschst-
33342, 10 μg/mL). After washing again with PBS, the coverslips were imaged using a 
confocal microscope (LSM710; Carl Zeiss Inc., Thornwood, NY). To quantify secondary 
antibody fluorescence, an outline was drawn at the perimeter of endothelial cells and a 
measurement of the average fluorescence was taken from several cells in each image.   
 
 
S1P2 Expression in Pulmonary Microvessels 
 
In IPLs from Cx43fl/fl and EC-Cx43-/- mice, a PE10 microcatheter was inserted 
through the left atrium and used to infuse HBS to clear a small section of the 
microvasculature of blood. Near a targeted post-capillary venule, an alveoli was 
micropunctured and filled with 2% Sudan black in oil to be used as a marker. A venule 
was then micropunctured and an instillation mixture of either Thrombin (10 U/mL) or 
PBS with RDx70 (.5 mg/mL) was given over 10 minutes. The RDx70 fluorescence was 
used to confirm instillation into the vasculature and to delineate treated microvessels. 
Microvessels in the cleared area were then fixed and permeabilized via catheter, with 30 
minute infusions of 3.7% paraformaldehyde and 0.05% Triton X, respectively. Following 
a 30 minute blocking infusion of 5% bovine serum albumin, successive infusions of S1P2 
primary Ab in HBS for 30 minutes, HBS alone for 20 minutes, and finally CF488A-
conjugated secondary Ab for 30 minutes were given to fluorescently tag the S1P2 protein 
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in the pulmonary microvasculature. Hoeschst-33342 was infused with the secondary 
antibody to stain the nuclei. Following staining, confocal images were obtained both in 
the area of micropuncture instillation as well as outside (600+ μm away from treated 
microvessels). The nuclear stain was used to define vessel location in images with low 
CF488A-conjugated secondary Ab fluorescence. Secondary antibody fluorescence was 
measured at random sites along the microvasculature both within and outside of the 
treated vessels, and several vessels were measured in each image.  
 
 
Thrombin-induced ROS Generation 
 
In isolated perfuse lungs from Cx43fl/fl and EC-Cx43-/- mice, a PE10 microcatheter 
was used to clear an area of the vasculature and to give a 30 minute infusion of CellROX 
deep red reagent and Calcein AM. Following a 30 minute equilibration period during an 
HBS infusion, confocal images were taken of two separate venules 600+ μm apart. One 
of the imaged venules was then micropunctured with either Thrombin (10 U/mL) or PBS 
with RDx70 (.5 mg/mL) instilled over 10 minutes. The two previously targeted venules 
were then imaged again. CellROX and Calcein AM fluorescence was measured at 
random sites along the microvasculature in both areas, before and immediately after the 
micropuncture instillation. The change in the ratio of CellROX/Calcein AM fluorescence 
was used to determine induction of ROS generation. As this is a live-cell process, and 
CellROX fluorescence may decrease naturally even though ROS amounts continue to 
increase (by prolonged, continued oxidation of the dye), the Calcein AM fluorescence 
was used as a guide to ensure that increases or decreases in ROS generation were 
adequately determined.  
 
In experiments to investigate S1P/S1P2-induced changes in ROS generation, a 
PE10 microcatheter was used to clear a section of the vasculature of Cx43fl/fl mouse 
lungs and CellROX and Calcein AM were infused for 30 min. Following the 
equilibration period, confocal z-stack images were taken of approximately 4 different 
areas surrounding a venule. Next, an infusion of either Thrombin (10 U/mL; 10 minutes) 
or S1P (10 μM; 20 minutes) was given via the microcatheter, with or without a 15 minute 
pretreatment infusion of JTE-013 (1 μL/mL). After treating the microvasculature, z-stack 
images were taken again of the same venular areas and changes in ROS were determined 
as described above. 
 
 
Microvascular Permeability 
 
In isolated perfused Cx43fl/fl mouse lungs, a PE10 microcatheter was used to clear 
an area of microvessels. Following treatment of Thrombin (10 U/mL; 10 minutes) or S1P 
(10 μM; 20 minutes), an infusion of FDx20 (.5 mg/mL) was given over 1 hour. At least 
20 minutes prior to the end of the FDx20 infusion, imaging was started, taking 1 image of 
the FDx20 fluorescence every minute, centered at a single microvessel. At the end of the 
FDx20 infusion, an infusion of HBS was started and continued for a minimum of 30 
minutes, with imaging continuing at the same rate. FDx20 fluorescence was measured at 
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random sites along the vasculature for the duration of the image series. Permeability was 
determined by normalizing the peak FDx20 fluorescence to 1000 AU and calculating the 
average decrease in intensity over the first 10 minutes following the peak. In experiments 
in which S1P2 signaling was inhibited, JTE-013 (1 μL/mL) was infused for 15 minutes 
prior to treatment. In experiments were ROS generation was inhibited, NAC (5 μM) was 
given for 1 hour prior to treatment. In experiments where thrombin and S1P were given at 
the same time, first S1P was infused for 10 minutes and then both S1P and thrombin were 
infused for an additional 10 minutes. 
 
 
Statistics 
 
All data reported as mean ± SEM. All groups were compared with Kruskal-Wallis 
one-way ANOVA on Ranks, followed by pairwise multiple comparisons by Dunn’s 
method. 
 
 
Results 
 
 
Thrombin Induces Differing Effects on S1P2 Expression in Both PMVECs and 
Microvessels in Cx43fl/fl and EC-Cx43-/- Mice 
 
S1P2 expression in PMVECs isolated from Cx43fl/fl and EC-Cx43-/- mouse 
lungs following thrombin treatment. While different inflammatory mediators have 
been shown to induce an increase in S1P2 expression in endothelial cells [70], this effect 
has not been studied in relation to thrombin. We first established expression of the S1P2 
receptor in primary PMVECs at baseline and following thrombin treatment. Briefly, from 
both Cx43fl/fl and EC-Cx43-/-mice, we removed the lungs, isolated the microvascular 
endothelial cells, and allowed them to adhere and grow on coverslips overnight. The cells 
were then fixed, permeabilized, and S1P2 expression was determined using 
immunofluorescence (Figure 4-1A). Primary endothelial cells isolated from Cx43fl/fl and 
EC-Cx43-/-mouse lungs showed similar levels of baseline fluorescence, with the EC-
Cx43-/- cells exhibiting slightly higher secondary Ab fluorescence (Cx43fl/fl baseline = 
236.0 ± 17.7 gy lvls; EC-Cx43-/- baseline = 347.3 ± 27.6 gy lvls). Interestingly, EC-Cx43-
/- cells that had been treated with thrombin prior to fixing displayed a slightly decreased 
S1P2 expression compared to baseline (EC-Cx43-/- thrombin = 249.3 ± 20.1 gy lvls). The 
opposite effect was observed in the Cx43fl/fl primary PMVECs in which thrombin 
induced a dramatic and significant increase in S1P2 expression (Cx43fl/fl thrombin = 
1099.0 ± 25.2 gy lvls)(Figure 4-1B). Overall, this shows that thrombin treatment leads to 
an increase in S1P2 expression in Cx43fl/fl, but not EC-Cx43-/-, isolated PMVECs.  
 
S1P2 expression in pulmonary microvessels. We further explored thrombin-
induced S1P2 expression in the pulmonary microvasculature of isolated Cx43fl/fl and EC-
Cx43-/- mouse lungs. Similar to what was done in the isolated cells, S1P2 expression was  
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Figure 4-1. S1P2 expression in mouse PMVECs 
(A,B) Confocal images and graph of immunofluorescence of S1P2 in isolated PMVECs 
from Cx43fl/fl (first column) and EC-Cx43-/- (second column) mice, at baseline (first row) 
and after thrombin (second row, 10 U/mL) treatment. Bars = 5 μm. *** = p<.001, **** = 
p<.0001 compared to Cx43fl/fl + thrombin treatment. n = 3 coverslips for all groups. 
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determined by immunofluorescence. At baseline, we found that in the Cx43fl/fl lungs there 
was a low level of S1P2 expression in both the venules and the capillaries (Figure 4-2A). 
However, in the EC-Cx43-/- mouse lungs we saw strikingly higher levels of S1P2 
expression, with immunofluorescence being approximately 5x and 15x what was seen in 
the Cx43fl/fl capillaries and venules, respectively (Figure 4-2B). This result was 
particularly surprising because, while EC-Cx43-/- cells displayed elevated S1P2 
expression over Cx43fl/fl cells, this was modest and not significant.  
 
We next studied S1P2 expression following local micropuncture instillations of 
either thrombin or PBS (for control). Similar to what was observed in the isolated 
PMVECs, thrombin treatment induced an increase in S1P2-mediated fluorescence in both 
venules and capillaries (Figure 4-3A). For both, while the increase inside the actual 
thrombin-treated microvessels was minor, the increase in venules and capillaries ~600μm 
away from the micropunctured area was quite sizeable and significantly higher compared 
to inside (Figure 4-3B and C). These results indicate that the thrombin treatment induced 
an increase in the presence of S1P2 in microvessels directly treated and in neighboring, 
untreated microvessels. 
 
Conversely, thrombin induced the opposite effect in the microvessels of the EC-
Cx43-/- mouse lungs (Figure 4-4A). In the venules, there was an insignificant increase 
over PBS control within the treated area. In the outside venules, thrombin treatment 
actually led to a significant decrease in S1P2 expression compared to both the directly 
thrombin-treated venules as well as venules outside of the PBS-treated area (Figure 4-
4B). In the capillaries, thrombin treatment induced a significant decrease in S1P2 
immunofluorescence compared to PBS control both within and outside of the 
micropunctured areas (Figure 4-4C). Thus, the absence of Cx43 in endothelial cells 
blunts thrombin-induced S1P2 responses. 
 
In comparing the results from Cx43fl/fl and EC-Cx43-/- lungs, while there was no 
significant difference between thrombin-treated venules of the two genotypes, there were 
significant differences between the outside venules as well as the inside and outside 
capillaries from the Cx43fl/fl and EC-Cx43-/- mouse lungs (Figure 4-5). Therefore, while 
there is significantly more S1P2 present in pulmonary microvascular endothelium of EC-
Cx43-/- mice at baseline, thrombin treatment induces an increase in expression in both 
directly-treated and faraway microvessels of the Cx43fl/fl mouse lungs as well as an 
overall decrease in S1P2 expression in the EC-Cx43-/- lung microvessels. 
 
 
Induction of ROS Generation by Thrombin in Pulmonary Microvessels 
 
We next chose to explore thrombin-induced generation of ROS in microvessels 
following local thrombin treatment, as ROS may be generated through PAR-1-depedent 
activation of Nox2 [51, 156]. We have previously shown that thrombin is able to induce 
F-actin polymerization in both thrombin-treated and –free microvessels   
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Figure 4-2. Baseline S1P2 expression in mouse pulmonary microvessels 
(A,B) Confocal images and graph of immunofluorescence of S1P2 in pulmonary 
microvessels of Cx43fl/fl and EC-Cx43-/- mouse lungs at baseline. Bars = 100 μm. **** = 
p<.0001 compared to Cx43fl/fl microvessels. n = 3 lungs for both genotypes. 
  
 49 
 
 
 
Figure 4-3. S1P2 expression in microvessels of Cx43fl/fl mouse lungs instilled with 
PBS or Thrombin 
(A) Confocal images of immunofluorescence of S1P2 in pulmonary microvessels of 
Cx43fl/fl mouse lungs following micropuncture instillation of either PBS (first column) or 
thrombin (second column,10 U/mL) treatment. Images captured in (first row) and out 
(second row) of micropunctured area. Bars = 100 μm. (B,C) Graphs showing S1P2 
immunofluorescence normalized to baseline levels in venules (B) and capillaries (C). *** 
= p<.001, **** = p<.0001 compared to microvessels outside of thrombin-treated area. n 
= 3 for PBS-treated lungs. n = 4 for thrombin-treated lungs. 
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Figure 4-4. S1P2 expression in microvessels of EC-Cx43-/- mouse lungs instilled 
with PBS or Thrombin 
(A) Confocal images of immunofluorescence of S1P2 in pulmonary microvessels of EC-
Cx43-/- mouse lungs following micropuncture instillation of either PBS (first column) or 
thrombin (second column,10 U/mL) treatment. Images captured in (first row) and out 
(second row) of micropunctured area. Bars = 100 μm. (B,C) Graphs showing S1P2 
immunofluorescence normalized to baseline levels in venules (B) and capillaries (C). 
(B)* = p<.05 compared to venules outside of thrombin-treated region. (C) * = p<.05, *** 
= p<.001 compared to capillaries in PBS-treated lungs in indicated areas. n = 3 for both 
treatment groups. 
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Figure 4-5. Comparison of S1P2 expression following Thrombin treatment in 
pulmonary microvessels of Cx43fl/fl and EC-Cx43-/- mouse lungs 
(A,B) Bar graphs depict S1P2 immunofluorescence following thrombin treatment 
normalized to baseline, untreated values in venules (A) and capillaries (B). **** = 
p<.0001 compared to Cx43fl/fl microvessels in indicated areas. n = 4 Cx43fl/fl mouse 
lungs, n = 3 EC-Cx43-/- mouse lungs. 
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by intercellular communication through Cx43-containing gap junctions [155], and we 
sought to determine if this other mediator of the thrombin permeability response may be 
induced in a similar spatially extensive manner. We evaluated ROS generation as the 
change in the ratio of CellROX deep red reagent (an indicator of ROS) fluorescence over 
Calcein AM fluorescence, before and after a micropuncture instillation of either thrombin 
or PBS. Thrombin induced significant increases in ROS within treated microvessels, with 
the change in the CellROX/Calcein AM ratio being double what was seen in PBS control 
for both treated venules and capillaries (Figure 4-6). Thrombin treatment also lead to 
increases in the untreated microvessels, with the change in the CellROX/Calcein AM 
ratio being double and triple control values for the venules and capillaries, respectively. 
 
However, in the EC-Cx43-/-, thrombin was able to induce only modest increases 
within thrombin-treated venules and capillaries that were not significant compared to 
control (Figure 4-7). In the untreated venules outside of the thrombin treatment, there 
was a significant decrease in the generation of ROS compared to treated venules, with 
values being nearly identical to PBS instillation values. In the outside capillaries, there 
was a minor increase compared to PBS instillation, but there was still less of a change in 
the CellROX/Calcein AM ratio compared to capillaries within the thrombin treated 
region.  
 
Overall, there was a significantly higher increase in ROS generation following 
thrombin treatment in all evaluated venules and the outside capillaries of Cx43fl/fl mouse 
lungs when compared to EC-Cx43-/- pulmonary microvasculature (Figure 4-8). Thus, 
thrombin induces increases in ROS generation in treated and faraway, untreated 
microvessels, and the spatial expansion of this response in dependent on Cx43-containing 
gap junctions. 
 
 
S1P2 Signaling Contributes to Thrombin-Induced Increase in Pulmonary 
Microvascular Permeability 
 
As both PAR-1 and S1P2 signaling has been shown to be barrier-destructive and 
stems from the activation of the same G-proteins, we evaluated whether or not there was 
any cooperation between the two pathways in pulmonary endothelial hyperpermeability. 
 
S1P, through its receptor S1P2, increases lung microvascular permeability. 
We first established the consequences of S1P2 signaling in permeability of pulmonary 
microvessels. To that end, following treatment with S1P with or without the S1P2 
antagonist JTE-013, we infused FDx20 kDa via catheter for 60 minutes. We determined 
the fall in fluorescence within the first 10 minutes after peak FDx20 fluorescence and 
switch to HBS infusion (calculated as gray levels/min). Therefore, the higher the gy 
lvls/min value, the more FDx20 kDa is washing out, the lower the permeability. 
Interestingly, we found that in this microvascular bed S1P itself induced a statistically 
significant increase in permeability compared to control (no treatment) and microvessels 
treated with JTE-013(Figure 4-9 A,B). However, when S1P2 signaling was blocked by a 
JTE-013 pretreatment, this increase was likewise blocked. We also sought to determine 
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Figure 4-6. Induction of ROS generation following Thrombin micropuncture 
instillation in microvessels of Cx43fl/fl mouse lungs 
(A) Confocal images of CellROX deep red reagent fluorescence (first column), Calcein 
AM fluorescence (second column), and merge of the two (third column) following 
thrombin micropuncture instillation in Cx43fl/fl mouse lungs. Images captured inside 
instillation area before (first row) and after (second row) thrombin (10 U/mL) treatment, 
as well as outside micropunctured area before (third row) and after (fourth row) 
treatment. Bars = 100 μm. (B,C) Bar graphs show the ratio of CellROX deep red reagent 
fluorescence over Calcein AM fluorescence, normalized to values before micropuncture 
instillation of either PBS or thrombin (10 U/mL), in venules (B) and capillaries (C). * = 
p<.05, ** = p<.01 compared to values obtained in PBS-instilled lungs in indicated areas. 
n = 3 for both treatment groups. 
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Figure 4-7. Induction of ROS generation following Thrombin micropuncture 
instillation in microvessels of EC-Cx43-/- mouse lungs 
(A) Confocal images of CellROX deep red reagent fluorescence (first column), Calcein 
AM fluorescence (second column), and merge of the two (third column) following 
thrombin micropuncture instillation in EC-Cx43-/- mouse lungs. Images captured inside 
instillation area before (first row) and after (second row) thrombin (10 U/mL) treatment, 
as well as outside micropunctured area before (third row) and after (fourth row) 
treatment. Bars = 100 μm. (B,C) Bar graphs show the ratio of CellROX deep red reagent 
fluorescence over Calcein AM fluorescence, normalized to values before micropuncture 
instillation of either PBS or thrombin (10 U/mL), in venules (B) and capillaries (C). * = 
p<.05 compared to values obtained in venules inside thrombin-treated area. n = 3 PBS-
treated lungs, n = 4 thrombin-treated lungs. 
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Figure 4-8. Comparison of ROS generation following Thrombin treatment in 
pulmonary microvessels of Cx43fl/fl and EC-Cx43-/- mouse lungs 
(A,B) Bar graphs show ratio of CellROX deep red reagent fluorescence over Calcein AM 
fluorescence, normalized to values before micropuncture instillation of thrombin (10 
U/mL), in venules (A) and capillaries (B). ** = p<.01, *** = p<.001, **** = p<.0001 
compared to Cx43fl/fl microvessels in indicated areas. n = 3 Cx43fl/fl lungs, n = 4 EC-
Cx43-/- lungs. 
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Figure 4-9. S1P2 signaling in pulmonary microvascular permeability 
(A) Pseudocolored images showing FDx20 fluorescence at peak (first column) and 5 
minutes into HBS wash following peak FDx20 fluorescence (second column) in Cx43fl/fl 
mouse lungs following treatment with JTE-013 (first row, 1 μM), S1P (second row, 10 
μM), S1P + JTE-013 (third row), thrombin (fourth row, 10U/ml) or thrombin+JTE-013 
(fifth row). Bars = 100 μm. (B,C) Bar graph shows the change in FDx20 fluorescence, as 
gray levels/min, following microcatheter infusion of indicated treatments. (B)** = p<.01, 
****=p<.0001 compared to thrombin alone, respectively.. $=p<.05, $$=p<.01 compared 
to S1P alone, respectively. n = 4 for control, S1P-, S1P+JTE-013-, and thrombin-treated 
lungs, n = 5 for JTE-013- and thrombin+JTE-013-treated lungs. (C) * = p<.05, ** = 
p<.01 compared thrombin followed by S1P treatment. n = 4 thrombin-treated lungs, n = 3 
thrombin+S1P-treated lungs, n = 3 thrombin- THEN S1P-treated lungs. 
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Figure 4-9 (Continued)  
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the depth to which S1P2 signaling may contribute to thrombin-induced increases in 
permeability in pulmonary microvessels. As observed previously, a catheter infusion of 
thrombin greatly increased endothelial barrier permeability compared to control and 
treatment with JTE-013 alone (Figure 4-9 A,B). However, when JTE-013 was used to 
prior to thrombin infusion, barrier integrity returned to control levels (Figure 4-9B). 
These results show that, in lung microvessels, signaling originating from the S1P2 
receptor leads to barrier disruption and that S1P2 signaling plays a role in thrombin-
induced permeability increases. 
 
To further study this relationship, as well as the effects of increased S1P 
production, we examined the consequences on permeability of giving S1P both 
concurrently with thrombin as well as following thrombin treatment. We found that when 
S1P is given following thrombin infusion, there is a significantly diminished impact on 
permeability compared to S1P given during thrombin as well as to thrombin alone 
(Figure 4-9C). This shows that S1P application, given following treatment with the 
inflammatory mediator thrombin, may help to alleviate the hyperpermeability response. 
 
Inhibition of S1P2 signaling pathways blocks thrombin-induced ROS 
generation in Cx43fl/fl pulmonary microvasculature. Because we observed both that 
S1P2 signaling was able to augment thrombin-induced signaling and that S1P itself can 
induce an increase in permeability, we next sought to establish whether signaling through 
S1P2 had any effect on thrombin-initiated ROS production. For this, we again used the 
change in the ratio of CellROX fluorescence over Calcein AM fluorescence, before and 
after treatment with thrombin and/or JTE-013, to determine changes in ROS content of 
the microvasculature. As we observed in previous experiments, thrombin infusion 
initiated a significant increase in ROS (Figure 4-10). However, when thrombin was 
given following infusion of JTE-013, this increase was completely abolished. In addition, 
we found that S1P treatment also lead to an increase in ROS generation that was blocked 
by JTE-013 pre-treatment. Thus, S1P2 signaling is required for the thrombin- and S1P-
induced increase in ROS production in pulmonary microvessels. 
 
Increases in permeability induced by S1P and thrombin are due to increases 
in ROS generation. Finally, we sought to investigate whether the increase in ROS 
generation that is being mediated by S1P2 is also responsible for the subsequent changes 
to barrier integrity induced by thrombin and S1P. Towards this, the microvessels were 
pretreated with NAC, an antioxidant and inhibitor of ROS generation. We found that 
blocking ROS generation completely abolished increases in permeability due to thrombin 
and S1P (Figure 4-11). Thus, the increased ROS generation induced by thrombin and 
S1P is mediating the increased permeability caused by these two inflammatory mediators. 
 
 
Discussion 
 
This study shows for the first time that, in both isolated primary PMVECs as well 
as in pulmonary microvessels from Cx43fl/fl mouse lungs, the inflammatory mediator  
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Figure 4-10. S1P2 signaling in Thrombin-induced ROS generation 
(A) Confocal images of CellROX deep red reagent fluorescence (first column), Calcein 
AM fluorescence (second column), and merge of the two (third column) before and after 
treatment of microvasculature with JTE-013 (1 μM) and/or thrombin (10 U/mL) in EC-
Cx43-/- mouse lungs. Bars = 100 μm. (B) Bar graph shows the ratio of CellROX deep 
red reagent fluorescence over Calcein AM fluorescence, normalized to values before 
treatment with indicated agents. *** = p<.001 compared to thrombin treatment group. 
$=p<.05, $$$=p<.001 compared to S1P treatment group. n = 3 for JTE-013-, 
thrombin+JTE-013-, S1P-, and S1P+JTE-013-treated lungs. n = 4 for thrombin-treated 
lungs. 
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Figure 4-10 (Continued)  
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Figure 4-11. Inhibition of ROS generation in S1P- and Thrombin-induced 
hyperpermeability 
(A) Bar graph shows the change in FDx20 fluorescence, as gray levels/min, following 
microcatheter infusion of indicated treatments. ***=p<.001, ****=P<.0001 compared to 
thrombin treatment group. $$=p<.01, $$$=p<.001 compared to S1P treatment group.  
n=4 for S1P- and thrombin-treated lungs; n=3 for NAC-, thrombin+NAC-, and 
S1P+NAC-treatedgroups. (B) Line graph shows average decline in FDx20 fluorescence 
within first 10 minutes of Ringer’s wash for each indicated treatment. Fluorescence 
normalized such that “Peak” fluor. equals 1000 gray levels. 
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thrombin induces an increase in S1P2 expression. In contrast, while at baseline S1P2 
expression was significantly higher in EC-Cx43-/- lungs than in Cx43fl/fl mouse lungs, 
thrombin treatment induces a general decrease in S1P2 expression in pulmonary 
microvessels of EC-Cx43-/- mouse lungs. S1P2 signaling contributes significantly to 
thrombin-induced increased microvascular permeability, and blocking S1P2 signaling 
greatly attenuates that permeability increase. In addition, this is the first study to examine 
whether thrombin-induced increases in ROS may be spatially expansive and shows 
increases in both locally-treated and neighboring, untreated microvessels of Cx43fl/fl 
mouse lungs. In EC-Cx43-/- mouse lungs, however, there was no significant increase in 
ROS production with thrombin treatment compared to PBS treatment. Interestingly, this 
study is the first to show that, while S1P may not affect the vascular barrier to the extent 
of thrombin, S1P alone induces increases in microvascular permeability, and this affect 
was mediated by the activation of S1P2 and subsequent increases in ROS generation. 
 
The data suggests that, as has been observed in various inflammatory states and 
with the treatment of inflammatory mediators, thrombin treatment induces an increase in 
the expression of S1P2 in endothelial cells. In addition, thrombin induced this effect in 
both thrombin-treated and –free microvessels within the Cx43fl/fl mouse lungs. This 
suggests the involvement of intercellular diffusion of second messengers, as this increase 
was not seen in endothelial cells or microvessels of mouse lungs lacking the major gap 
junction protein Cx43. This second messenger and the specific thrombin-induced 
signaling mechanism leading to this change in S1P2 expression is unclear and requires 
further elucidation. Activation of the thrombin receptor PAR-1 has been shown to 
activate SphK1, which subsequently leads to an increase in S1P production [63, 157]. In 
turn, the S1P is exported from the cell by various ABC transporters, most notably spinster 
homolog 2 (Spns2) in endothelial cells [65, 67, 71]. Following export, S1P itself has been 
shown to be a second messenger and acts in a paracrine, or even autocrine, manner to 
activate S1P receptors on neighboring cells [62, 70, 158-160]. In one study, treatment 
with S1P was shown to cause an increase in S1P2 mRNA in a thyroid cell line [161]. In 
another study, preadipocytes cultured with S1P showed a greater expression of S1P2 
receptor than when not cultured with S1P [162]. It is possible that this may point to the 
mechanism by which thrombin acts on S1P2 expression. PAR-1 activation leads to 
increased S1P, and the S1P is exported from the cell and acts upon nearby cells to lead to 
an increase in the S1P2 receptor. Interestingly, thrombin induced a greater increase in 
S1P2 in thrombin-free microvessels far removed from the thrombin instillation region in 
the Cx43fl/fl mouse lungs. As we begin fixing the lung surface immediately following 
thrombin treatment, it could be that thrombin was already able to induce increases in both 
S1P2 expression and S1P production. However, in the thrombin-treated area, the newly-
generated S1P has already had the opportunity to bind to the newly-expressed S1P2 
receptors and lead to their internalization. This and other possible mechanisms by which 
thrombin and/or PAR-1 activation may affect S1P2 membrane expression necessitate 
further examination. 
 
Intriguingly, basal S1P2 expression was significantly higher in endothelial cells 
and microvessels of EC-Cx43-/- mouse lungs compared to Cx43fl/fl, and thrombin 
treatment curiously led to a decrease in S1P2. S1P signaling is a relatively new field of 
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research, and S1P has only really been seen as an important mediator within the past 15 
years. There have been a few studies showing a relationship between S1P and Cx43 
expression and communication, but these focus on S1P signaling and not an association 
or relationship with a specific receptor. One group found that, in cardiomyocytes, S1P 
treatment led to a decrease in gap junction intercellular communication by inducing 
phosphorylation of Cx43 specifically at serine 368, and this effect was blocked by 
inhibiting S1P2 signaling [163, 164]. On the other hand, in astrocytes S1P treatment has 
also been shown to inhibit gap junction communication by dephosphorylation of Cx43 
[165, 166]. In addition, in differentiating myoblasts, S1P treatment induced increases in 
both Cx43 mRNA and protein levels and also increased gap junction communication 
[167]. This response was dependent upon S1P activation of Ca2+- and p38-MAPK-
dependent pathways. However, while these studies detail the effect of S1P on Cx43, there 
has been no studies exploring how Cx43 may effect S1P signaling or if there exists an 
association between Cx43 and S1P receptors. In addition, there has been no 
investigations as to the regulation of Cx43 function by S1P in endothelial cells. Our 
results do suggest that gap junction communication itself is not involved in the intensified 
expression in the knockout line as our studies in isolated mouse PMVECs used non-
confluent cells. The observed difference in S1P2 expression, both at baseline and 
following thrombin treatment, in the EC-Cx43-/- mouse line adds another link in the 
connection between S1P signaling and Cx43-containing gap junctions, and this 
connection requires further study. 
 
This study is the first to detail the contributions of S1P2 signaling to 
microvascular permeability increases induced by thrombin. It has been determined that 
S1P signaling is generally barrier protective, but this has primarily been attributed to 
signaling through the S1P1 receptor [168, 169]. Using our Cx43fl/fl mouse line, we show 
that under normal conditions S1P signaling did not enhance the microvascular barrier but 
infact lead to a statistically significant decrease in barrier integrity, and this 
hyperpermeability was prevented with the use of the S1P2 antagonist JTE-013. In 
thrombin-induced microvascular hyperpermeability, blocking S1P2 signaling also 
effectively blocked the increase in permeability. The effect of using JTE-013 during 
thrombin treatment was quite striking and seems to suggests that, in pulmonary 
microvessels, S1P2 signaling is a major factor in the induction of increased 
microvascular permeability by thrombin. Following this, we wanted to explore the role of 
S1P in protecting the microvascular barrier in inflammation. We treated microvessels 
with thrombin and S1P, both simultaneously as well as consecutively. We observed that 
while S1P given during thrombin challenge provided no benefit, there was a significant 
difference in the thrombin-induced response when S1P was given following treatment 
with the inflammatory mediator. These results support the conclusion that 
pharmacological targeting of S1P2 may be effective in combating inflammatory 
mediator-induced increases in pulmonary microvascular permeability, and suggest 
delayed therapy may be more effective to particularly amerliorate hypermeability 
mediated by thrombin [153, 170-172].  
 
In addition, we explored the ability of thrombin-induced signaling to increase 
ROS generation in pulmonary microvessels. Using local micropuncture instillations of 
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thrombin, we observed subsequent significant increases in ROS in both thrombin-treated 
and –free microvessels in Cx43fl/fl mouse lungs. Conversely, we found little to no increase 
in ROS in the EC-Cx43-/- lungs. This would suggest that, indeed, increases in ROS in the 
microvessels outside of the instillation area in the Cx43fl/fl lungs requires intercellular 
communication. Interestingly, in both thrombin-induced increases in ROS generation as 
well as S1P2 expression, the response in EC-Cx43-/- lungs was lower compared to 
Cx43fl/fl lungs, even within the thrombin-treated microvessels. We observed a similar 
relationship in a previous study in which thrombin-induced increases in F-actin 
polymerization were less pronounced in the thrombin-treated vessels of the EC-Cx43-/- 
mouse lungs compared to microvessels from Cx43fl/fl mice [155]. This would suggest the 
involvement of intercellular communication of second messengers to see the full 
response to thrombin, even in the treated areas, due to the presense of pacemaker cells 
and the heterogenous distribution of membrane receptors. These results highlight the 
importance of using physiological relevant models, such as IPL, to study responses in 
intact tissues and organs. 
 
We further investigated whether S1P2 may play a role in thrombin induction of 
ROS generation, and found that the thrombin-induced increase that is observed in these 
microvessels is dependent on S1P2 signaling. When these microvessels were pre-treated 
with the S1P2 receptor blocker JTE-013 prior to thrombin, virtually no increase in ROS 
was observed. Additionally, we found that, in pulmonary microvascular endothelial cells, 
S1P itself induces an increase in ROS generation that was dependent on activation of 
S1P2. Through subsequent permeability experiments utilizing the ROS blocker NAC, we 
determined that the increase in permeability induced by S1P was due to the increase in 
ROS mediated by S1P2. 
 
Increases in ROS due to inflammatory mediators, including thrombin, have been 
shown to contribute to hyperpermeability through the disruption of AJs [173]. While a 
link between S1P-induced changes in ROS generation has been studied, the direct effect 
of S1P receptor signaling on ROS generation is unclear, as S1P has been shown to induce 
increases and decreases in ROS depending on the cell type [64]. In one study, treatment 
of HLMVECs with S1P was shown to induce increases in ROS generation [174], 
however the contributions of specific receptors was not investigated. In another study in 
HUVECs, it was observed that treatment with high glucose concentrations increased both 
S1P2 expression and ROS generation, and that blocking the increase in S1P2 was able to 
subsequently block the increase in ROS production [175]. Our results here show that, not 
only does signaling through S1P2 lead to increased ROS generation in lung 
microvascular endothelial cells, but also that this increase is mediating the increase in 
permeability induced by both S1P and thrombin. 
 
In summary, while at baselinse microvascular endothelium lacking gap junction 
protein Cx43 has a higher expression of S1P2 compared to normal, thrombin induces 
increases in treated and faraway, untreated microvessels of Cx43fl/fl mouse lungs that are 
absent in the EC-Cx43-/- microvessels. S1P2 signaling negatively regulates microvascular 
barrier integrity both at baseline and in thrombin-induced hyperpermeability. Blocking 
S1P2 was able to block the thrombin-induced increase in permeability, and S1P given 
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post-thrombin treatment helped to rescue barrier integrity. S1P2 signaling was found to 
mediate increases in ROS generation induced by both thrombin and S1P treatment, and it 
it through this ROS increase that S1P is able to induce increases in microvascular 
permeability. Similar to S1P2 expression, local thrombin treatment induced increases in 
ROS generation in both treated and non-treated microvessels of Cx43fl/fl mouse lungs. 
With both thrombin-induced increases in S1P2 expression and ROS production, the 
response was considerably smaller in treated EC-Cx43-/- microvessels compared to those 
in Cx43fl/fl, suggesting the involvement of pacemaker endothelial cells and intercellular 
communication. These results demonstrate the involvement of S1P2 signaling in 
hyperpermeability stimulated by inflammatory mediators, the role of intercellular 
communication in thrombin-induced endothelial responses, and bring into focus the need 
for physiologically relevant models to study inflammation. 
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CHAPTER 5.    CONCLUSION 
 
 
Summary 
 
In the studies detailed in this dissertation, we employed the physiologically-
relevant model of isolated perfused lungs to study signaling initiated by inflammatory 
mediators. We focused on the signaling mechanisms related to the induction of increased 
permeability, which in the lungs presents itself as a particularly harmful response that 
may often lead to death.  
 
In studies involving thrombin, we examined responses that have been extensively 
studied in endothelial monolayers but not in actual microvessels. We studied thrombin-
induced responses of F-actin polymerization, ROS generation, and microvascular 
hyperpermeability. We used micropuncture instillations to observe how thrombin may 
trigger these effects not just in microvessels directly treated with thrombin but also in 
faraway and untreated microvessels. In the case of F-actin polymerization, we found that 
local thrombin application may trigger significant increases in treated microvessels as 
well as microvessels up to 0.7mm away when compared to PBS instillations. Similarly, 
thrombin micropuncture instillation was able to induce significant increases in ROS in 
microvessels inside the treated area as well in microvessels roughly 0.6 mm outside the 
instillation area, and increases in microvascular permeability itself where seen within and 
outside of local thrombin treatment. These results showed that, in pulmonary 
microvessels thrombin activation of PAR-1 led to spatially extensive responses such that 
both microvessels directly treated with the inflammatory mediator and those far away 
showed evidence of signaling that may lead to increased microvascular permeability. 
 
We determined the role of Cx43-containing gap junctions in terms of the spatial 
expansion of these thrombin responses. In endothelial-specific Cx43 knockout mice, 
thrombin micropuncture instillation was unable to initiate the same degree of increase as 
was seen in the floxed-control mice in F-actin polymerization or ROS generation in either 
the microvessels outside the thrombin treatment site or even within microvessels directly 
treated with the inflammatory mediator. In the case of microvascular permeability, the 
use of the gap junction inhibitor Gap27 had no significant effect on the endothelial 
integrity in microvessels in the treated site or the immediate, neighboring microvessels. 
However, microvessels approximately 150 μm outside of the instillation area began 
exhibiting significantly less permeability compared to thrombin alone treatment, and 
microvessels approximately 300 μm outside approached PBS control values. As it is clear 
that the spread of these thrombin-induced responses was dependent on intercellular 
communication through Cx43 containing gap junctions, we endeavored to determine the 
specific second messenger communicated and dictating these responses in the outside 
microvessels. Intracellular Ca2+ concentration mediates these responses in endothelial 
cells. As PAR-1 activation induces the generation of IP3, which then initiates a 
subsequent increase in intracellular Ca2+, and both of these molecules may be diffused 
intercellularly through gap junctions, we used the ER IP3R inhibitor XeC to curtail this 
signaling. Pretreatment of all microvessels with XeC via catheter infusion blocked the 
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thrombin-induced increase in F-actin polymerization, demonstrating the requirement for 
IP3-induced Ca2+ release in this response. We then gave overlapping micropuncture 
instillations of thrombin and XeC. In this way, if Ca2+ alone was mediating the  response 
in the outside microvessels, even in those treated with XeC, Ca2+ would be free to 
intercellularly diffuse into this area and induce the F-actin increase. However, we 
observed that focal XeC application blocked the thrombin-induced increase in F-actin 
polymerization. In addition, to confirm that IP3 may be intercellularly diffused and 
initiate responses in endothelial cells of intact microvessels, we used a caged-IP3 
molecule (NPE-IP3) in UV photolysis experiments in which we also co-loaded vessels 
with the fluorescence calcium indicator Fluo4 AM. We observed increases in Ca2+ in 
microvessels within and outside of the UV uncaging site. These results demonstrate that 
IP3 is the specific second messenger mediating the spatial expansion of F-actin 
polymerization in pulmonary microvessels.  
 
We also wanted to explore the relationship between thrombin- and S1P2-mediated 
signaling, as well as the role of Cx43-containing gap junctions in this relationship. We 
confirmed expression of the sphingolipid receptor S1P2 in cells and microvessels of both 
floxed Cx43 mouse lungs as well as lungs from endothelial-specific Cx43 knockout mice. 
Interestingly, we observed a significantly higher level of S1P2 expression in microvessels 
from the EC-Cx43-/- compared to Cx43fl/fl. However, though we observed a dramatic 
increase in S1P2 following thrombin treatment in Cx43fl/fl pulmonary endothelial cells 
and microvessels, we were unable to detect similar increases in the absence of Cx43 
expression. We then studied S1P2 signaling in relation to endothelial barrier integrity. 
We observed that in the absence of pro-inflammatory signaling in pulmonary 
microvessels, there was a major increase in microvascular permeability with S1P 
treatment, and this was blocked with treatment of the S1P2 antagonist JTE-013. When 
the microvessels were treated with thrombin via a microcatheter infusion, JTE-013 also 
blocked the thrombin-induced hyperpermeability, and microvascular integrity remained 
at control values. To determine whether S1P signaling in general may alleviate thrombin-
induced increases in permeability, we treated microvessels with both mediators, both 
together and sequentially. We saw no difference when S1P was given with thrombin. 
However, we observed a significantly lower increase in permeability when S1P was 
given following thrombin infusion. We next explored possible mechanisms by which 
signaling via S1P2 may mediate the permeability increase. We found that increases in 
ROS generation due to both thrombin and S1P were blocked when the microvessels were 
pretreated with JTE-013. Further, we found that inhibiting ROS production attenuated the 
increase in permeability induced by S1P. These results showed that thrombin, like other 
inflammatory mediators, initiates pro-inflammatory signaling leading to increased 
expression of S1P2 at the membrane of endothelial cells. In addition, they shed light on a 
previously unknown relationship between S1P and thrombin in the induction of 
hyperpermeability in pulmonary microvessels. 
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Future Directions 
 
In endothelial cells, thrombin activation of PAR-1 induces change in intracellular 
Ca2+ in two phases: first through the release of ER Ca2+ stores, then a subsequent 
induction of external calcium entry. These changes in cytosolic Ca2+ precede the 
responses studied here, including ROS generation [9, 51]. While we show here that, like 
F-actin polymerization and microvascular permeability, the thrombin-induced increase in 
ROS is a spatially extensive response spreading far outside the treatment region, what is 
unknown is the second messenger being communicated for this specific response. It is 
probable that, like what was observed in F-actin polymerization, IP3 is the mediating 
signaling molecule in this case as well. In addition to the increased ROS generation being 
mediated by changes in cytosolic Ca2+ and therefore IP3, IP3 is logically the more 
efficient signaling molecule. The movement of IP3 into a cell and activation of its 
receptor leads to a much greater change in cytosolic Ca2+ than intercellular movement of 
Ca2+ molecules alone. Thus, a similar experiment as to what was done for F-actin 
polymerization, using micropuncture instillations of an IP3R blocker, would be beneficial 
in making this determination. 
 
The insights gained from these experiments highlight the utility of ex vivo and in 
situ models in studying inflammation in the lung. Our results showing that thrombin 
induces increases in Ca2+ oscillation amplitude rather than mean Ca2+ in particular show 
the differences between studying these signaling mechanisms in intact tissues versus 
cultured cells. The responses induced by thrombin here were rapid, usually occurring 
within 10 minutes of thrombin treatment. Key to the repair of the endothelial barrier is 
the reannealing of the interendothelial junctions [176]. In addition to activation of RhoA, 
thrombin-induced inactivation of Rac1 can lead to the disruption of AJs and contribute to 
increased permeability. In endothelial monolayers, it has been seen that interendothelial 
junctions reseal 1-2 hours after beginning  sustained thrombin challenge [126]. It is 
unknown, however, how sustained thrombin treatment may effect permeability of lung 
microvessels. Therefore, future studies investigating the effects of a longer, sustained 
thrombin treatment in pulmonary microvessels may further reveal valuable information 
towards the repair of this microvascular bed following increased permeability. 
 
In pulmonary microvessels, we observed an interesting trend in that thrombin-
induced responses were attenuated in the absence of Cx43, even in the directly treated 
vessels. Numerous studies have already shown the effects of intercellular communication 
in inflammation, including the contributions made by Cx43-containing gap junctions to 
the severity of hyperpermeability and edema formation in lung inflammation [72, 73, 79, 
81, 90]. However, those studies tend to look at whole monolayer or whole tissue 
permeability, in which all affected cells have been treated with the permeability-inducing 
agent and/or have a reduction in Cx43 expression or function, and are therefore unable to 
explore spatial expansion of signaling outside of a focal treated area. These are the first 
results to show that, not only does inhibiting or knocking out Cx43 seem to block the 
spatial expansion of a detrimental response into untreated or healthy tissues, but also that 
blocking intercellular communication affects the gravity of the response even within the 
treated pulmonary microvessels. This clearly points to the therapeutic utility of limiting 
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gap junctional communication in inflammation. Indeed, though not approved specifically 
for lung inflammation, one such drug, carbenoxolone (CBX), is currently used to treat 
gastrointestinal inflammation. In studies looking at the effects of this drug in the lung, 
CBX was found to block increases in cytokine expression and infiltration of 
inflammatory cells in a murine asthma model [177]. In a CLP model of sepsis and lung 
inflammation, CBX blocked secretions of high-mobility group box protein 1 (HMGB1), a 
late pro-inflammatory mediator and a negative indicator of survival in sepsis [178, 179]. 
Thus, studies that more closely examine the use of gap junction blockers in clinical 
models of lung inflammation will likely show them to be beneficial towards survival. 
 
In conclusion, our data detail: the spatially-extensive induction of responses by 
thrombin that contribute to increased microvascular permeability in lung inflammation; 
demonstrate the specific signaling molecule being intercellularly communicated through 
Cx43-containing gap junctions for the thrombin-induced increase in F-actin 
polymerization; show that S1P2 expression is affected by thrombin treatment and that 
this is dependent on the presence of Cx43 in the cell; and that S1P2-mediated signaling 
contributes substantially to the induction of increased microvascular permeability by 
thrombin. These experiments utilized a physiologically-relevant model to study responses 
that were both dependent on receptor activation by inflammatory mediators as well as 
contributed to the detrimental hyperpermeability response seen in lung inflammation. The 
results highlight previous work towards the importance of intercellular communication in 
the spread of inflammatory responses while also providing a hereto unseen visualization 
and quantification on the extent of the spread into unchallenged tissues. They also point 
out a novel relationship between Cx43, thrombin, and S1P2 expression, and also the 
contributions of S1P2 signaling in thrombin-induced pulmonary microvascular 
disruption.  
 
  
 75 
LIST OF REFERENCES 
 
 
1. Price, L.C., et al., Pathophysiology of pulmonary hypertension in acute lung 
injury. American Journal of Physiology - Lung Cellular and Molecular 
Physiology, 2012. 302(9): p. L803-L815. 
2. Evans, C.E. and Y.-Y. Zhao, Impact of thrombosis on pulmonary endothelial 
injury and repair following sepsis. American Journal of Physiology - Lung 
Cellular and Molecular Physiology, 2017. 312(4): p. L441-L451. 
3. Koh, Y., How to approach the acute respiratory distress syndrome: Prevention, 
plan, and prudence. Respiratory Investigation, 2017. 55(3): p. 190-195. 
4. Opal, S.M. and T. van der Poll, Endothelial barrier dysfunction in septic shock. 
Journal of Internal Medicine, 2015. 277(3): p. 277-293. 
5. Reiss, L.K. and S. Uhlig, Toward the Molecular Signature of Acute Respiratory 
Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 
2016. 194(8): p. 922-924. 
6. Gill, S.E., C.M. Yamashita, and R.A.W. Veldhuizen, Lung remodeling associated 
with recovery from acute lung injury. Cell and Tissue Research, 2017. 367(3): p. 
495-509. 
7. Confalonieri, M., F. Salton, and F. Fabiano, Acute respiratory distress syndrome. 
European Respiratory Review, 2017. 26(144). 
8. Parissopoulos, S., M.D.A. Mpouzika, and F. Timmins, Optimal support 
techniques when providing mechanical ventilation to patients with acute 
respiratory distress syndrome. Nursing in Critical Care, 2017. 22(1): p. 40-51. 
9. Vandenbroucke, E., et al., Regulation of Endothelial Junctional Permeability. 
Annals of the New York Academy of Sciences, 2008. 1123(1): p. 134-145. 
10. Schnoor, M., et al., Actin dynamics in the regulation of endothelial barrier 
functions and neutrophil recruitment during endotoxemia and sepsis. Cellular and 
Molecular Life Sciences, 2017. 74(11): p. 1985-1997. 
11. Millar, F.R., et al., The pulmonary endothelium in acute respiratory distress 
syndrome: insights and therapeutic opportunities. Thorax, 2016. 71(5): p. 462-
473. 
12. Hickey, M.J. and C.L.V. Westhorpe, Imaging inflammatory leukocyte recruitment 
in kidney, lung and liver[mdash]challenges to the multi-step paradigm. Immunol 
Cell Biol, 2013. 91(4): p. 281-289. 
13. Mai, J., et al., An evolving new paradigm: endothelial cells – conditional innate 
immune cells. Journal of Hematology & Oncology, 2013. 6(1): p. 61. 
14. Murakami, K. and D.L. Traber, Pathophysiological Basis of Smoke Inhalation 
Injury. Physiology, 2003. 18(3): p. 125. 
15. Barletta, K.E., et al., Leukocyte compartments in the mouse lung: Distinguishing 
between marginated, interstitial, and alveolar cells in response to injury. Journal 
of Immunological Methods, 2012. 375(1–2): p. 100-110. 
16. Barnes, P.J., Inflammatory mechanisms in patients with chronic obstructive 
pulmonary disease. J Allergy Clin Immunol, 2016. 138(1): p. 16-27. 
17. Mokra, D. and P. Kosutova, Biomarkers in acute lung injury. Respiratory 
Physiology & Neurobiology, 2015. 209: p. 52-58. 
 76 
18. Aman, J., et al., Using cultured endothelial cells to study endothelial barrier 
dysfunction: Challenges and opportunities. American Journal of Physiology - 
Lung Cellular and Molecular Physiology, 2016. 311(2): p. L453-L466. 
19. Herwig, M.C., et al., Vascular Endothelial Cadherin Expression in Lung 
Specimens of Patients with Sepsis-Induced Acute Respiratory Distress Syndrome 
and Endothelial Cell Cultures. Pathobiology, 2013. 80(5): p. 245-251. 
20. Liu, M.-W., et al., Effect of Melilotus suaveolens extract on pulmonary 
microvascular permeability by downregulating vascular endothelial growth 
factor expression in rats with sepsis. Molecular Medicine Reports, 2015. 11(5): p. 
3308-3316. 
21. Chelazzi, C., et al., Glycocalyx and sepsis-induced alterations in vascular 
permeability. Critical Care, 2015. 19(1): p. 26. 
22. Monahan, L.J., Acute Respiratory Distress Syndrome. Current Problems in 
Pediatric and Adolescent Health Care, 2013. 43(10): p. 278-284. 
23. Gill, S.E., et al., Pulmonary Microvascular Albumin Leak Is Associated with 
Endothelial Cell Death in Murine Sepsis-Induced Lung Injury In Vivo. PLoS 
ONE, 2014. 9(2): p. e88501. 
24. Mondrinos, M.J., et al., Pulmonary Endothelial Protein Kinase C-Delta (PKCδ) 
Regulates Neutrophil Migration in Acute Lung Inflammation. The American 
Journal of Pathology, 2014. 184(1): p. 200-213. 
25. Iwasaki, A. and R. Medzhitov, Control of adaptive immunity by the innate 
immune system. Nat Immunol, 2015. 16(4): p. 343-353. 
26. Müller-Redetzky, H.C., N. Suttorp, and M. Witzenrath, Dynamics of pulmonary 
endothelial barrier function in acute inflammation: mechanisms and therapeutic 
perspectives. Cell and Tissue Research, 2014. 355(3): p. 657-673. 
27. Salvador, B., et al., Modulation of endothelial function by Toll like receptors. 
Pharmacological Research, 2016. 108: p. 46-56. 
28. Nickols, J., et al., Lipopolysaccharide-induced pulmonary endothelial barrier 
disruption and lung edema: critical role for bicarbonate stimulation of AC10. 
American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015. 
309(12): p. L1430-L1437. 
29. Müller-Redetzky, H.C., et al., Mechanical ventilation drives pneumococcal 
pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. 
Critical Care, 2014. 18(2): p. R73-R73. 
30. Kuebler, W.M., Inflammatory pathways and microvascular responses in the lung. 
Pharmacol Rep, 2005. 57 Suppl: p. 196-205. 
31. Looney, M.R. and J. Bhattacharya, Live Imaging of the Lung. Annual Review of 
Physiology, 2014. 76(1): p. 431-445. 
32. Garcia Ponce, A., et al., Loss of cortactin causes endothelial barrier dysfunction 
via disturbed adrenomedullin secretion and actomyosin contractility. Sci Rep, 
2016. 6: p. 29003. 
33. Tasaka, S., et al., Attenuation of endotoxin-induced acute lung injury by the Rho-
associated kinase inhibitor, Y-27632. Am J Respir Cell Mol Biol, 2005. 32(6): p. 
504-10. 
34. de Prost, N., et al., Effects of ventilation strategy on distribution of lung 
inflammatory cell activity. Critical Care, 2013. 17(4): p. R175-R175. 
 77 
35. Ochiai, R., Mechanical ventilation of acute respiratory distress syndrome. Journal 
of Intensive Care, 2015. 3(1): p. 25. 
36. Wang, T., et al., Endothelial cell signaling and ventilator-induced lung injury: 
molecular mechanisms, genomic analyses, and therapeutic targets. American 
Journal of Physiology - Lung Cellular and Molecular Physiology, 2017. 312(4): p. 
L452-L476. 
37. Komarova, Y.A., et al., Protein Interactions at Endothelial Junctions and 
Signaling Mechanisms Regulating Endothelial Permeability. Circulation 
Research, 2017. 120(1): p. 179-206. 
38. Tian, X., et al., Asef controls vascular endothelial permeability and barrier 
recovery in the lung. Molecular Biology of the Cell, 2015. 26(4): p. 636-650. 
39. Ganter, M.T., et al., Role of Small GTPases and αvβ5 Integrin in Pseudomonas 
aeruginosa–Induced Increase in Lung Endothelial Permeability. American 
Journal of Respiratory Cell and Molecular Biology, 2009. 40(1): p. 108-118. 
40. Grommes, J. and O. Soehnlein, Contribution of Neutrophils to Acute Lung Injury. 
Molecular Medicine, 2011. 17(3-4): p. 293-307. 
41. Tauseef, M., et al., TLR4 activation of TRPC6-dependent calcium signaling 
mediates endotoxin-induced lung vascular permeability and inflammation. The 
Journal of Experimental Medicine, 2012. 209(11): p. 1953-1968. 
42. Goldenberg, N.M. and W.M. Kuebler, Endothelial Cell Regulation of Pulmonary 
Vascular Tone, Inflammation, and Coagulation, in Comprehensive Physiology. 
2015, John Wiley & Sons, Inc. 
43. Souza, M.C., T.A. Padua, and M.G. Henriques, Endothelial-Leukocyte Interaction 
in Severe Malaria: Beyond the Brain. Mediators of Inflammation, 2015. 2015: p. 
168937. 
44. Ploppa, A., et al., Mechanisms of leukocyte distribution during sepsis: an 
experimental study on the interdependence of cell activation, shear stress and 
endothelial injury. Critical Care, 2010. 14(6): p. R201. 
45. Schmidt, E.P., et al., The pulmonary endothelial glycocalyx regulates neutrophil 
adhesion and lung injury during experimental sepsis. Nature medicine, 2012. 
18(8): p. 10.1038/nm.2843. 
46. Gane, J. and R. Stockley, Mechanisms of neutrophil transmigration across the 
vascular endothelium in COPD. Thorax, 2012. 67(6): p. 553-561. 
47. Saffarzadeh, M., et al., Neutrophil Extracellular Traps Directly Induce Epithelial 
and Endothelial Cell Death: A Predominant Role of Histones. PLoS ONE, 2012. 
7(2): p. e32366. 
48. Caudrillier, A., et al., Platelets induce neutrophil extracellular traps in 
transfusion-related acute lung injury. The Journal of Clinical Investigation, 2012. 
122(7): p. 2661-2671. 
49. Narasaraju, T., et al., Excessive Neutrophils and Neutrophil Extracellular Traps 
Contribute to Acute Lung Injury of Influenza Pneumonitis. The American Journal 
of Pathology, 2011. 179(1): p. 199-210. 
50. Tiruppathi, C., et al., Role of Ca2+ signaling in the regulation of endothelial 
permeability. Vascul Pharmacol, 2002. 39(4-5): p. 173-85. 
 78 
51. Andrikopoulos, P., et al., Endothelial Angiogenesis and Barrier Function in 
Response to Thrombin Require Ca(2+) Influx through the Na(+)/Ca(2+) 
Exchanger. The Journal of Biological Chemistry, 2015. 290(30): p. 18412-18428. 
52. Gill, S.E., M. Rohan, and S. Mehta, Role of pulmonary microvascular endothelial 
cell apoptosis in murine sepsis-induced lung injury in vivo. Respiratory Research, 
2015. 16(1): p. 109. 
53. Mehta, D. and A.B. Malik, Signaling Mechanisms Regulating Endothelial 
Permeability. Physiological Reviews, 2006. 86(1): p. 279-367. 
54. Finigan, J.H., The coagulation system and pulmonary endothelial function in 
acute lung injury. Microvascular Research, 2009. 77(1): p. 35-38. 
55. Bogatcheva, N.V., et al., Molecular mechanisms mediating protective effect of 
cAMP on lipopolysaccharide (LPS)-induced human lung microvascular 
endothelial cells (HLMVEC) hyperpermeability. Journal of cellular physiology, 
2009. 221(3): p. 750-759. 
56. Kandasamy, K., et al., Changes in endothelial connexin 43 expression inversely 
correlate with microvessel permeability and VE-cadherin expression in 
endotoxin-challenged lungs. American Journal of Physiology - Lung Cellular and 
Molecular Physiology, 2015. 309(6): p. L584-L592. 
57. Banerjee, A., et al., Hyperosmolarity attenuates TNFα–mediated pro-
inflammatory activation of human pulmonary microvascular endothelial cells. 
Shock (Augusta, Ga.), 2013. 39(4): p. 366-372. 
58. Abraham, E., et al., Efficacy and safety of monoclonal antibody to human tumor 
necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, 
double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. 
Jama, 1995. 273(12): p. 934-41. 
59. Raghavendran, K., et al., Pharmacotherapy of Acute Lung Injury and Acute 
Respiratory Distress Syndrome. Current medicinal chemistry, 2008. 15(19): p. 
1911-1924. 
60. Oishi, H., et al., Olprinone and colforsin daropate alleviate septic lung 
inflammation and apoptosis through CREB-independent activation of the Akt 
pathway. American Journal of Physiology - Lung Cellular and Molecular 
Physiology, 2012. 303(2): p. L130-L140. 
61. Wilkerson, B.A. and K.M. Argraves, The role of sphingosine-1-phosphate in 
endothelial barrier function. Biochimica et Biophysica Acta (BBA) - Molecular 
and Cell Biology of Lipids, 2014. 1841(10): p. 1403-1412. 
62. Mahajan-Thakur, S., et al., Sphingosine-1-Phosphate and Its Receptors: A Mutual 
Link between Blood Coagulation and Inflammation. Mediators of Inflammation, 
2015. 2015: p. 831059. 
63. Billich, A., et al., Sphingosine kinase 1 is essential for proteinase-activated 
receptor-1 signalling in epithelial and endothelial cells. The International Journal 
of Biochemistry & Cell Biology, 2009. 41(7): p. 1547-1555. 
64. Herr, D.R., et al., Sphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive 
oxygen species formation and inhibits cell death: implications for otoprotective 
therapy. 2016. 6: p. 24541. 
 79 
65. Olivera, A., M.L. Allende, and R.L. Proia, Shaping the landscape: Metabolic 
regulation of S1P gradients. Biochimica et biophysica acta, 2013. 1831(1): p. 
193-202. 
66. Zhang, W., et al., Sphingosine-1-phosphate receptor-2 mediated NFκB activation 
contributes to tumor necrosis factor-α induced VCAM-1 and ICAM-1 expression 
in endothelial cells. Prostaglandins & Other Lipid Mediators, 2013. 106: p. 62-71. 
67. Rauch, B.H., Sphingosine 1-Phosphate as a Link between Blood Coagulation and 
Inflammation. Cellular Physiology and Biochemistry, 2014. 34(1): p. 185-196. 
68. Igarashi, J., et al., Hydrogen peroxide induces S1P&lt;sub&gt;1&lt;/sub&gt; 
receptors and sensitizes vascular endothelial cells to sphingosine 1-phosphate, a 
platelet-derived lipid mediator. American Journal of Physiology - Cell 
Physiology, 2007. 292(2): p. C740. 
69. Sanchez, T., et al., Induction of Vascular Permeability by the Sphingosine-1-
Phosphate Receptor–2 (S1P2R) and its Downstream Effectors ROCK and PTEN. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 2007. 27(6): p. 1312. 
70. Du, J., et al., LPS and TNF-α induce expression of sphingosine-1-phosphate 
receptor-2 in human microvascular endothelial cells. Pathology - Research and 
Practice, 2012. 208(2): p. 82-88. 
71. Yanagida, K. and T. Hla, Vascular and Immunobiology of the Circulatory 
Sphingosine 1-Phosphate Gradient. Annual Review of Physiology, 2017. 79(1): 
p. 67-91. 
72. Sarieddine, M.Z.R., et al., Connexin43 modulates neutrophil recruitment to the 
lung. Journal of Cellular and Molecular Medicine, 2009. 13(11-12): p. 4560-4570. 
73. Scheckenbach, K.E., et al., Connexin channel-dependent signaling pathways in 
inflammation. J Vasc Res, 2011. 48(2): p. 91-103. 
74. Nielsen, M.S., et al., Gap junctions. Compr Physiol, 2012. 2(3): p. 1981-2035. 
75. Abed, A., et al., Targeting connexin 43 protects against the progression of 
experimental chronic kidney disease in mice. Kidney Int, 2014. 86(4): p. 768-779. 
76. Langer, J., et al., Gap junctions mediate intercellular spread of sodium between 
hippocampal astrocytes in situ. Glia, 2012. 60(2): p. 239-252. 
77. Shintani-Ishida, K., K. Unuma, and K.-i. Yoshida, Ischemia Enhances 
Translocation of Connexin43 and Gap Junction Intercellular Communication, 
Thereby Propagating Contraction Band Necrosis After Reperfusion. Circulation 
Journal, 2009. 73(9): p. 1661-1668. 
78. Decrock, E., et al., Transfer of IP3 through gap junctions is critical, but not 
sufficient, for the spread of apoptosis. Cell Death Differ, 2012. 19(6): p. 947-957. 
79. O’Donnell, J.J., III, et al., Gap Junction Protein Connexin43 Exacerbates Lung 
Vascular Permeability. PLOS ONE, 2014. 9(6): p. e100931. 
80. Takenaka, T., et al., Expression and role of connexins in the rat renal vasculature. 
Kidney Int, 2007. 73(4): p. 415-422. 
81. Parthasarathi, K., Endothelial connexin43 mediates acid-induced increases in 
pulmonary microvascular permeability. Am J Physiol Lung Cell Mol Physiol, 
2012. 303(1): p. L33-42. 
82. Nikolian, V.C., et al., Lung Protective Effects of Low-Volume Resuscitation and 
Pharmacologic Treatment of Swine Subjected to Polytrauma and Hemorrhagic 
Shock. Inflammation, 2017. 40(4): p. 1264-1274. 
 80 
83. Schnyder-Candrian, S., et al., Neutrophil Inhibitory Factor Selectively Inhibits the 
Endothelium-Driven Transmigration of Eosinophils In Vitro and Airway 
Eosinophilia in OVA-Induced Allergic Lung Inflammation. Journal of Allergy, 
2012. 2012: p. 245909. 
84. Uhlig, S., et al., Differential regulation of lung endothelial permeability in vitro 
and in situ. Cell Physiol Biochem, 2014. 34(1): p. 1-19. 
85. Fazal, F., et al., Critical Role of Non-Muscle Myosin Light Chain Kinase in 
Thrombin-Induced Endothelial Cell Inflammation and Lung PMN Infiltration. 
PLoS ONE, 2013. 8(3): p. e59965. 
86. Nahar, K., et al., In vitro, in vivo and ex vivo models for studying particle 
deposition and drug absorption of inhaled pharmaceuticals. European Journal of 
Pharmaceutical Sciences, 2013. 49(5): p. 805-818. 
87. Sanchez, P.G., et al., State of Art: Clinical ex vivo lung perfusion: Rationale, 
current status, and future directions. The Journal of Heart and Lung 
Transplantation, 2012. 31(4): p. 339-348. 
88. Fry, T., J.H. Evans, and M.J. Sanderson, Propagation of intercellular calcium 
waves in C6 glioma cells transfected with connexins 43 or 32. Microsc Res Tech, 
2001. 52(3): p. 289-300. 
89. Paemeleire, K., Calcium signaling in and between brain astrocytes and 
endothelial cells. Acta Neurol Belg, 2002. 102(3): p. 137-40. 
90. Parthasarathi, K., et al., Connexin 43 mediates spread of Ca2+-dependent 
proinflammatory responses in lung capillaries. J Clin Invest, 2006. 116(8): p. 
2193-200. 
91. Kanaporis, G., et al., Gap junction channels exhibit connexin-specific 
permeability to cyclic nucleotides. J Gen Physiol, 2008. 131(4): p. 293-305. 
92. Godecke, S., et al., Thrombin-induced ATP release from human umbilical vein 
endothelial cells. Am J Physiol Cell Physiol, 2012. 302(6): p. C915-23. 
93. Weir, E.K. and S.L. Archer, The mechanism of acute hypoxic pulmonary 
vasoconstriction: the tale of two channels. The FASEB Journal, 1995. 9(2): p. 
183-9. 
94. Wang, L., et al., Hypoxic pulmonary vasoconstriction requires connexin 40-
mediated endothelial signal conduction. J Clin Invest, 2012. 122(11): p. 4218-30. 
95. Ichimura, H., et al., Lung surfactant secretion by interalveolar Ca2+ signaling. 
Am J Physiol Lung Cell Mol Physiol, 2006. 291(4): p. L596-601. 
96. Lum, H., et al., Calcium dependence of the thrombin-induced increase in 
endothelial albumin permeability. J Appl Physiol (1985), 1989. 66(3): p. 1471-6. 
97. Wang, Z., et al., Calcium/Calmodulin-dependent Protein Kinase II Delta 6 
(CaMKIIδ(6)) and RhoA Involvement in Thrombin-induced Endothelial Barrier 
Dysfunction. The Journal of Biological Chemistry, 2010. 285(28): p. 21303-
21312. 
98. Gudermann, T. and D. Steinritz, STIMulating stress fibers in endothelial cells. Sci 
Signal, 2013. 6(267): p. pe8. 
99. Arachiche, A., et al., Protease-activated Receptor 1 (PAR1) and PAR4 
Heterodimers Are Required for PAR1-enhanced Cleavage of PAR4 by α-
Thrombin. Journal of Biological Chemistry, 2013. 288(45): p. 32553-32562. 
 81 
100. Liao, Y., et al., Endothelial cell-specific knockout of connexin 43 causes 
hypotension and bradycardia in mice. Proceedings of the National Academy of 
Sciences of the United States of America, 2001. 98(17): p. 9989-9994. 
101. Kandasamy, K., G. Sahu, and K. Parthasarathi, Real-time imaging reveals 
endothelium-mediated leukocyte retention in LPS-treated lung microvessels. 
Microvasc Res, 2012. 83(3): p. 323-31. 
102. Kandasamy, K. and K. Parthasarathi, Quantifying single microvessel permeability 
in isolated blood-perfused rat lung preparation. J Vis Exp, 2014(88): p. e51552. 
103. Kandasamy, K., et al., Lipopolysaccharide induces endoplasmic store Ca2+-
dependent inflammatory responses in lung microvessels. PLoS One, 2013. 8(5): p. 
e63465. 
104. Thiede, B.R. and J.T. Corwin, Permeation of fluorophore-conjugated phalloidin 
into live hair cells of the inner ear is modulated by P2Y receptors. J Assoc Res 
Otolaryngol, 2014. 15(1): p. 13-30. 
105. Gonzales, J.N., et al., Low anticoagulant heparin blocks thrombin-induced 
endothelial permeability in a PAR-dependent manner. Vascular Pharmacology, 
2014. 62(2): p. 63-71. 
106. Adyshev, D.M., et al., Ezrin/radixin/moesin proteins differentially regulate 
endothelial hyperpermeability after thrombin. American Journal of Physiology - 
Lung Cellular and Molecular Physiology, 2013. 305(3): p. L240-L255. 
107. Kasa, A., et al., Protein phosphatase 2A activity is required for functional 
adherent junctions in endothelial cells. Microvasc Res, 2013. 89: p. 86-94. 
108. Rajput, C., et al., Neural Wiskott-Aldrich syndrome protein (N-WASP)-mediated 
p120-catenin interaction with Arp2-Actin complex stabilizes endothelial adherens 
junctions. J Biol Chem, 2013. 288(6): p. 4241-50. 
109. Szulcek, R., et al., Localized RhoA GTPase activity regulates dynamics of 
endothelial monolayer integrity. Cardiovascular Research, 2013. 99(3): p. 471-
482. 
110. Goligorsky, M.S., et al., Nature of thrombin-induced sustained increase in 
cytosolic calcium concentration in cultured endothelial cells. J Biol Chem, 1989. 
264(28): p. 16771-5. 
111. Wong, M.K. and A.I. Gotlieb, Endothelial monolayer integrity. Perturbation of 
F-actin filaments and the dense peripheral band-vinculin network. 
Arteriosclerosis, 1990. 10(1): p. 76-84. 
112. Minshall, R.D., et al., Role of protein kinase Czeta in thrombin-induced RhoA 
activation and inter-endothelial gap formation of human dermal microvessel 
endothelial cell monolayers. Microvasc Res, 2010. 80(2): p. 240-9. 
113. Murphy, J.T., et al., Thrombin-mediated permeability of human microvascular 
pulmonary endothelial cells is calcium dependent. J Trauma, 2001. 50(2): p. 213-
22. 
114. Tiruppathi, C., et al., Ca2+ signaling, TRP channels, and endothelial 
permeability. Microcirculation, 2006. 13(8): p. 693-708. 
115. Kameritsch, P., et al., Gap junctional communication controls the overall 
endothelial calcium response to vasoactive agonists. Cardiovascular Research, 
2012. 93(3): p. 508-515. 
 82 
116. Gafni, J., et al., Xestospongins: Potent Membrane Permeable Blockers of the 
Inositol 1,4,5-Trisphosphate Receptor. Neuron, 1997. 19(3): p. 723-733. 
117. Sauer, H., et al., Hypotonic Ca2+ signaling and volume regulation in 
proliferating and quiescent cells from multicellular spheroids. J Cell Physiol, 
1998. 175(2): p. 129-40. 
118. Singh, I., et al., Gαq-TRPC6-mediated Ca2+ Entry Induces RhoA Activation and 
Resultant Endothelial Cell Shape Change in Response to Thrombin. Journal of 
Biological Chemistry, 2007. 282(11): p. 7833-7843. 
119. Shinde, A.V., et al., STIM1 controls endothelial barrier function independently of 
Orai1 and Ca2+ entry. Sci Signal, 2013. 6(267): p. ra18. 
120. Dudek, S.M. and J.G. Garcia, Cytoskeletal regulation of pulmonary vascular 
permeability. J Appl Physiol (1985), 2001. 91(4): p. 1487-500. 
121. Vogel, S.M. and A.B. Malik, Cytoskeletal dynamics and lung fluid balance. 
Compr Physiol, 2012. 2(1): p. 449-78. 
122. Prasain, N. and T. Stevens, The actin cytoskeleton in endothelial cell phenotypes. 
Microvasc Res, 2009. 77(1): p. 53-63. 
123. Mehta, D. and A.B. Malik, Signaling Mechanisms Regulating Endothelial 
Permeability. Physiological Reviews, 2005. 86(1): p. 279-367. 
124. Werthmann, R.C., M.J. Lohse, and M. Bunemann, Temporally resolved cAMP 
monitoring in endothelial cells uncovers a thrombin-induced [cAMP] elevation 
mediated via the Ca(2)+-dependent production of prostacyclin. J Physiol, 2011. 
589(Pt 1): p. 181-93. 
125. Lohman, A.W., M. Billaud, and B.E. Isakson, Mechanisms of ATP release and 
signalling in the blood vessel wall. Cardiovasc Res, 2012. 95(3): p. 269-80. 
126. Aslam, M., et al., cAMP controls the restoration of endothelial barrier function 
after thrombin-induced hyperpermeability via Rac1 activation. Physiol Rep, 
2014. 2(10). 
127. Liu, F.-C., et al., The anti-aggregation effects of ondansetron on platelets involve 
IP3 signaling and MAP kinase pathway, but not 5-HT3-dependent pathway. 
Thrombosis Research, 2012. 130(3): p. e84-e94. 
128. Evans, J., et al., Arachidonic acid induces brain endothelial cell apoptosis via 
p38-MAPK and intracellular calcium signaling. Microvascular Research, 2015. 
98: p. 145-158. 
129. Bickler, P.E. and C.S. Fahlman, The Inhaled Anesthetic, Isoflurane, Enhances 
Ca2+-Dependent Survival Signaling in Cortical Neurons and Modulates MAP 
Kinases, Apoptosis Proteins and Transcription Factors During Hypoxia. 
Anesthesia & Analgesia, 2006. 103(2). 
130. Kása, A., C. Csortos, and A.D. Verin, Cytoskeletal mechanisms regulating 
vascular endothelial barrier function in response to acute lung injury. Tissue 
Barriers, 2015. 3(1-2): p. e974448. 
131. Hirano, S., et al., Endothelial barrier dysfunction caused by LPS correlates with 
phosphorylation of HSP27in vivo. Cell Biology and Toxicology, 2004. 20(1): p. 
1-14. 
132. Wolfson, R.K., E.T. Chiang, and J.G.N. Garcia, HMGB1 induces human lung 
endothelial cell cytoskeletal rearrangement and barrier disruption. Microvascular 
Research, 2011. 81(2): p. 189-197. 
 83 
133. Guay, J., et al., Regulation of actin filament dynamics by p38 map kinase-
mediated phosphorylation of heat shock protein 27. Journal of Cell Science, 1997. 
110(3): p. 357-368. 
134. Huot, J., et al., Oxidative Stress-Induced Actin Reorganization Mediated by the 
p38 Mitogen-Activated Protein Kinase/Heat Shock Protein 27 Pathway in 
Vascular Endothelial Cells. Circulation Research, 1997. 80(3): p. 383-392. 
135. Piotrowicz, R.S. and E.G. Levin, Basolateral Membrane-associated 27-kDa Heat 
Shock Protein and Microfilament Polymerization. Journal of Biological 
Chemistry, 1997. 272(41): p. 25920-25927. 
136. Huot, J., et al., SAPK2/p38-dependent F-Actin Reorganization Regulates Early 
Membrane Blebbing during Stress-induced Apoptosis. The Journal of Cell 
Biology, 1998. 143(5): p. 1361-1373. 
137. Sawada, J., F. Li, and M. Komatsu, R-Ras Inhibits VEGF-Induced p38MAPK 
Activation and HSP27 Phosphorylation in Endothelial Cells. Journal of Vascular 
Research, 2015. 52(5): p. 347-359. 
138. Wu, T., J. Xing, and A.A. Birukova, Cell-type-specific crosstalk between p38 
MAPK and Rho signaling in lung micro- and macrovascular barrier dysfunction 
induced by <em>Staphylococcus aureus</em>-derived pathogens. Translational 
Research, 2013. 162(1): p. 45-55. 
139. Parthasarathi, K., et al., Mitochondrial reactive oxygen species regulate spatial 
profile of proinflammatory responses in lung venular capillaries. J Immunol, 
2002. 169(12): p. 7078-86. 
140. Burns, A.R., C.W. Smith, and D.C. Walker, Unique structural features that 
influence neutrophil emigration into the lung. Physiol Rev, 2003. 83(2): p. 309-
36. 
141. Ofori-Acquah, S.F., et al., Heterogeneity of barrier function in the lung reflects 
diversity in endothelial cell junctions. Microvasc Res, 2008. 75(3): p. 391-402. 
142. Ying, X., et al., Ca2+ waves in lung capillary endothelium. Circ Res, 1996. 79(4): 
p. 898-908. 
143. Kawanami, O., et al., Heterogeneous distribution of thrombomodulin and von 
Willebrand factor in endothelial cells in the human pulmonary microvessels. J 
Nippon Med Sch, 2000. 67(2): p. 118-25. 
144. Chen, C.-H., et al., The connexin 43/ZO-1 complex regulates cerebral endothelial 
F-actin architecture and migration. American Journal of Physiology - Cell 
Physiology, 2015. 309(9): p. C600-C607. 
145. Machtaler, S., et al., The role of the gap junction protein connexin43 in B 
lymphocyte motility and migration. FEBS Letters, 2014. 588(8): p. 1249-1258. 
146. Matsuuchi, L. and C.C. Naus, Gap junction proteins on the move: Connexins, the 
cytoskeleton and migration. Biochimica et Biophysica Acta (BBA) - 
Biomembranes, 2013. 1828(1): p. 94-108. 
147. Ambrosi, C., et al., Connexin43 Forms Supramolecular Complexes through Non-
Overlapping Binding Sites for Drebrin, Tubulin, and ZO-1. PLOS ONE, 2016. 
11(6): p. e0157073. 
148. Olk, S., et al., Proteomic analysis of astroglial connexin43 silencing uncovers a 
cytoskeletal platform involved in process formation and migration. Glia, 2010. 
58(4): p. 494-505. 
 84 
149. Mehta, S. and J. Zhang, Dynamic visualization of calcium-dependent signaling in 
cellular microdomains. Cell Calcium, 2015. 58(4): p. 333-341. 
150. Itagaki, K., et al., Sphingosine 1-Phosphate Has Dual Functions in the Regulation 
of Endothelial Cell Permeability and Ca<sup>2+</sup> Metabolism. Journal of 
Pharmacology and Experimental Therapeutics, 2007. 323(1): p. 186-191. 
151. Li, X., et al., Role of protein kinase Cζ in thrombin-induced endothelial 
permeability changes: inhibition by angiopoietin-1. Blood, 2004. 104(6): p. 1716-
1724. 
152. Wei, X.N., et al., An Integrated Mathematical Model of Thrombin-, Histamine-
and VEGF-Mediated Signalling in Endothelial Permeability. BMC Systems 
Biology, 2011. 5: p. 112-112. 
153. Wang, Z., et al., Pharmacologic Targeting of Sphingosine-1-Phosphate Receptor 
1 Improves the Renal Microcirculation during Sepsis in the Mouse. The Journal 
of Pharmacology and Experimental Therapeutics, 2015. 352(1): p. 61-66. 
154. Sobel, K., et al., FTY720 Phosphate Activates Sphingosine-1-Phosphate Receptor 
2 and Selectively Couples to Galpha12/13/Rho/ROCK to Induce Myofibroblast 
Contraction. Mol Pharmacol, 2015. 87(6): p. 916-27. 
155. Escue, R., K. Kandasamy, and K. Parthasarathi, Thrombin Induces Inositol 
Trisphosphate-Mediated Spatially Extensive Responses in Lung Microvessels. The 
American Journal of Pathology, 2017. 187(4): p. 921-935. 
156. Huang, Q., et al., Activation of PAR-1/NADPH Oxidase/ROS Signaling Pathways 
is Crucial for the Thrombin-Induced sFlt-1 Production in Extravillous 
Trophoblasts: Possible Involvement in the Pathogenesis of Preeclampsia. Cellular 
Physiology and Biochemistry, 2015. 35(4): p. 1654-1662. 
157. Tauseef, M., et al., Activation of Sphingosine Kinase-1 Reverses the Increase in 
Lung Vascular Permeability Through Sphingosine-1-Phosphate Receptor 
Signaling in Endothelial Cells. Circulation Research, 2008. 103(10): p. 1164-
1172. 
158. Pyne, S. and N. Pyne, Sphingosine 1-phosphate signalling via the endothelial 
differentiation gene family of G-protein-coupled receptors. Pharmacology & 
Therapeutics, 2000. 88(2): p. 115-131. 
159. Kondo, S., et al., Memo Has a Novel Role in S1P Signaling and Crucial for 
Vascular Development. PLoS ONE, 2014. 9(4): p. e94114. 
160. Marfia, G., et al., Autocrine/paracrine sphingosine-1-phosphate fuels proliferative 
and stemness qualities of glioblastoma stem cells. Glia, 2014. 62(12): p. 1968-
1981. 
161. Björklund, S., et al., Effects of sphingosine 1-phosphate on calcium signaling, 
proliferation and S1P2 receptor expression in PC Cl3 rat thyroid cells. Molecular 
and Cellular Endocrinology, 2005. 231(1): p. 65-74. 
162. Moon, M.H., J.K. Jeong, and S.Y. Park, Activation of S1P2 receptor, a possible 
mechanism of inhibition of adipogenic differentiation by sphingosine 1phosphate. 
Mol Med Rep, 2015. 11(2): p. 1031-6. 
163. Morel, S., et al., The natural cardioprotective particle HDL modulates 
connexin43 gap junction channels. Cardiovascular Research, 2012. 93(1): p. 41-
49. 
 85 
164. Morel, S., et al., Sphingosine-1-phosphate reduces ischaemia–reperfusion injury 
by phosphorylating the gap junction protein Connexin43. Cardiovascular 
Research, 2016. 109(3): p. 385-396. 
165. Rouach, N., et al., S1P inhibits gap junctions in astrocytes: involvement of Gi and 
Rho GTPase/ROCK. European Journal of Neuroscience, 2006. 23(6): p. 1453-
1464. 
166. Tence, M., et al., Increased interaction of connexin43 with zonula occludens-1 
during inhibition of gap junctions by G protein-coupled receptor agonists. Cell 
Signal, 2012. 24(1): p. 86-98. 
167. Squecco, R., et al., Sphingosine 1-Phosphate Induces Myoblast Differentiation 
through Cx43 Protein Expression: A Role for a Gap Junction-dependent and -
independent Function. Molecular Biology of the Cell, 2006. 17(11): p. 4896-
4910. 
168. Yang, Y. and S. Uhlig, The role of sphingolipids in respiratory disease. 
Therapeutic Advances in Respiratory Disease, 2011. 5(5): p. 325-344. 
169. Sammani, S., et al., Differential effects of sphingosine 1-phosphate receptors on 
airway and vascular barrier function in the murine lung. Am J Respir Cell Mol 
Biol, 2010. 43(4): p. 394-402. 
170. Liu, W., et al., Sphingosine-1-phosphate receptor 2 mediates endothelial cells 
dysfunction by PI3K-Akt pathway under high glucose condition. Eur J Pharmacol, 
2016. 776: p. 19-25. 
171. Zhang, G., et al., Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in 
acute vascular inflammation. Blood, 2013. 122(3): p. 443-455. 
172. Kim, G.S., et al., Critical role of sphingosine-1-phosphate receptor-2 in the 
disruption of cerebrovascular integrity in experimental stroke. Nature 
Communications, 2015. 6: p. 7893. 
173. Mittal, M., et al., Reactive Oxygen Species in Inflammation and Tissue Injury. 
Antioxidants & Redox Signaling, 2014. 20(7): p. 1126-1167. 
174. Harijith, A., et al., Sphingosine Kinase 1 Deficiency Confers Protection against 
Hyperoxia-Induced Bronchopulmonary Dysplasia in a Murine Model. The 
American Journal of Pathology, 2013. 183(4): p. 1169-1182. 
175. Chen, et al., Role of sphingosine-1-phosphate receptor 1 and sphingosine-1-
phosphate receptor 2 in hyperglycemia-induced endothelial cell dysfunction. 
International Journal of Molecular Medicine, 2015. 35(4): p. 1103-1108. 
176. Bhattacharya, J. and M.A. Matthay, Regulation and repair of the alveolar-
capillary barrier in acute lung injury. Annu Rev Physiol, 2013. 75: p. 593-615. 
177. Ram, A., et al., Inhaled carbenoxolone prevents allergic airway inflammation and 
airway hyperreactivity in a mouse model of asthma. Int Arch Allergy Immunol, 
2009. 149(1): p. 38-46. 
178. Li, W., et al., Carbenoxolone Blocks Endotoxin-Induced Protein Kinase R (PKR) 
Activation and High Mobility Group Box 1 (HMGB1) Release. Molecular 
Medicine, 2013. 19(1): p. 203-211. 
179. Wang, H., et al., HMG-1 as a late mediator of endotoxin lethality in mice. 
Science, 1999. 285(5425): p. 248-51. 
 
  
 86 
VITA 
 
 
 Rachel Escue Helms was born in 1988 to Catherine Denise and Gregory Stephen 
Escue in Memphis, TN. In 2010, she earned her Bachelor of Science in Biomedical 
Sciences from Christian Brothers University. Following a “year off” during which she 
worked in Dr. Clinton Stewart’s lab in the Pharmaceutial Sciences department of St. Jude 
Children’s Research Hospital, Rachel matriculated into the Integrated Program of 
Biomedical Sciences at the University of Tennessee Health Science Center. Under the 
mentorship of Dr. Kaushik Parthasarathi, she completed her PhD candidacy in 2015 and 
defended her thesis work in September of 2018. She expects to graduate with her 
doctorate in Biomedical Sciences in December 2018. 
